{
  "schema_version": "0.1.0",
  "case_id": "HR-ML051",
  "record_classification": {
    "synthetic": true,
    "banner": "SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD",
    "real_historical_name": true,
    "public_release_status": "draft"
  },
  "identity": {
    "person_id": "ML051",
    "display_name": "Pablo Neruda",
    "aliases": [
      "Ricardo Eliecer Neftalí Reyes Basoalto"
    ],
    "sex": "male",
    "era": "Mid-Late 20th Century",
    "nationality": "Chilean",
    "historical_dates": {
      "birth": {
        "preferred": {
          "iso": "1904-07-12",
          "display": "12 July 1904",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1904",
              "display": "1904",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0011"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the Nobel Prize biography and the Library of the National Congress of Chile."
          }
        ]
      },
      "death": {
        "preferred": {
          "iso": "1973-09-23",
          "display": "23 September 1973",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1973",
              "display": "1973",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0011"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the National Library of Chile and the Library of the National Congress of Chile."
          }
        ]
      }
    },
    "synthetic_identity": {
      "mrn": "HR-ML051-SYN",
      "ssn": "000-51-2976",
      "date_of_birth": "1959-07-12",
      "name_policy": "real_historical_name",
      "fictional_facility": "St. Posthumous Health Center",
      "fictional_primary_clinician": "Marisol Fairweather-Diaz, MD",
      "fictional_consultant": {
        "name": "Étienne Okonkwo-Lund, MD",
        "specialty": "Medical Oncology (genitourinary)"
      }
    }
  },
  "historical_timeline": [
    {
      "event_id": "EVT-0001",
      "date": {
        "iso": "1904-07-12",
        "display": "12 July 1904",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Born in Parral, Chile.",
      "claim_ids": [
        "CLM-0001"
      ]
    },
    {
      "event_id": "EVT-0002",
      "date": {
        "iso": "1920",
        "display": "1920",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Begins publishing under the pen name Pablo Neruda.",
      "claim_ids": [
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0003",
      "date": {
        "iso": "1927",
        "display": "1927",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Begins a series of consular posts in Asia and later in Buenos Aires, Barcelona and Madrid (to 1935).",
      "claim_ids": [
        "CLM-0003"
      ]
    },
    {
      "event_id": "EVT-0004",
      "date": {
        "iso": "1945",
        "display": "1945",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Elected senator of the Republic.",
      "claim_ids": [
        "CLM-0003"
      ]
    },
    {
      "event_id": "EVT-0005",
      "date": {
        "iso": "1946-12-28",
        "display": "28 December 1946",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "A court judgment changes his birth name to Pablo Neruda.",
      "claim_ids": [
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0006",
      "date": {
        "iso": "1971-01-21",
        "display": "21 January 1971",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "The Senate approves his appointment as ambassador to France.",
      "claim_ids": [
        "CLM-0004"
      ]
    },
    {
      "event_id": "EVT-0007",
      "date": {
        "iso": "1971-07",
        "display": "July 1971",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Health problems begin; operated on for prostate cancer in France.",
      "claim_ids": [
        "CLM-0005"
      ]
    },
    {
      "event_id": "EVT-0008",
      "date": {
        "iso": "1971-10-21",
        "display": "21 October 1971",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Awarded the Nobel Prize in Literature.",
      "claim_ids": [
        "CLM-0006"
      ]
    },
    {
      "event_id": "EVT-0009",
      "date": {
        "iso": "1972-11",
        "display": "November 1972",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Resigns as ambassador and returns to Chile.",
      "claim_ids": [
        "CLM-0004"
      ]
    },
    {
      "event_id": "EVT-0010",
      "date": {
        "iso": "1973-09-23",
        "display": "23 September 1973",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Dies at the Clínica Santa María in Santiago, twelve days after the military coup; the death certificate gives cancer cachexia.",
      "claim_ids": [
        "CLM-0007",
        "CLM-0008"
      ]
    },
    {
      "event_id": "EVT-0011",
      "date": {
        "iso": "2013-11-08",
        "display": "8 November 2013",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Chile's medical legal service reports no relevant chemical substances in his exhumed remains.",
      "claim_ids": [
        "CLM-0009"
      ]
    },
    {
      "event_id": "EVT-0012",
      "date": {
        "iso": "2017-10",
        "display": "October 2017",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "An international forensic panel rejects cachexia as the cause of death without naming a cause.",
      "claim_ids": [
        "CLM-0010",
        "CLM-0013"
      ]
    },
    {
      "event_id": "EVT-0013",
      "date": {
        "iso": "2023-02",
        "display": "February 2023",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Clostridium botulinum DNA reported in a molar and bone; how it got there could not be determined.",
      "claim_ids": [
        "CLM-0011",
        "CLM-0013"
      ]
    },
    {
      "event_id": "EVT-0014",
      "date": {
        "iso": "2024-02-20",
        "display": "20 February 2024",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "The Santiago appeals court orders the investigation reopened.",
      "claim_ids": [
        "CLM-0012"
      ]
    }
  ],
  "claims": [
    {
      "claim_id": "CLM-0001",
      "statement": "Pablo Neruda was born on 12 July 1904 in the town of Parral in Chile. His father was a railway employee, and his mother, a teacher, died shortly after his birth; he spent his childhood and youth in Temuco.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the true birth date. His mother's cause of death is not recorded in the sources read.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "was born on 12 July, 1904, in the town of Parral in Chile. His father was a railway employee and his mother, who died shortly after his birth, a teacher"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "Nacimiento: 12 de Julio de 1904 Parral"
        },
        {
          "source_id": "SRC-0011",
          "relationship": "supports",
          "locator": "roster birth year 1904"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0002",
      "statement": "He used the pen name Pablo Neruda from 1920. The Nobel Prize biography gives his real name as Neftalí Ricardo Reyes Basoalto; the Library of the National Congress of Chile gives his birth name as Ricardo Eliecer Neftalí Reyes Basoalto and records that a court judgment of 28 December 1946 changed it to Pablo Neruda.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "Used for the display name and the alias. The two sources order the given names differently; the congressional biography's full form is used as the alias.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "whose real name is Neftalí Ricardo Reyes Basoalto ... under the pen name of Pablo Neruda"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "Por sentencia judicial, el 28 de diciembre de 1946, su nombre de nacimiento, Ricardo Eliecer Neftalí Reyes Basoalto, cambia por ... Pablo Neruda"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0003",
      "statement": "Between 1927 and 1935 he held a series of honorary consulships in Burma, Ceylon, Java, Singapore, Buenos Aires, Barcelona and Madrid; in 1945 he was elected a senator of the Republic and joined the Communist Party of Chile.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors his long diplomatic and public life in the modern social history.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "Between 1927 and 1935, the government put him in charge of a number of honorary consulships ... in 1945 he was elected senator of the Republic, also joining the Communist Party of Chile"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "Senador 1945 - 1953"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0004",
      "statement": "After the 1970 presidential election he was named Chile's ambassador to France; the Senate approved the appointment on 21 January 1971 and he presented his credentials at the end of that month. He resigned the post in 1972 and returned to Chile in November 1972.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors his occupation and his residence in Paris at the index date (June 1971). The brief gave the posting as 1970 to 1972; the sources date the appointment to January 1971.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "el 21 de enero de 1971, el Senado aprobó su nombramiento como embajador de Chile en París. A fines de ese mes presentó sus cartas credenciales"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "Neruda es designado como embajador de Chile ante el gobierno de Francia ... Renuncia a su cargo de embajador en Francia y regresa a Chile en noviembre"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0005",
      "statement": "In July 1971 he began to have health problems and was operated on for prostate cancer; during his convalescence in France he wrote Geografía infructuosa. Later reports describe him as suffering from prostate cancer at the time of his death.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "The documented anchor for prostate cancer in the modern episode. The congressional biography is the only source read that dates the diagnosis and the operation; the type of operation, the stage, the grade and any other treatment were not recorded in the sources read.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "En julio de 1971 comenzó a tener problemas de salud y fue operado de cáncer de próstata. Durante su convalecencia en Francia escribió Geografía infructuosa"
        },
        {
          "source_id": "SRC-0006",
          "relationship": "supports",
          "locator": "he was 69 and suffered from prostate cancer at the time of his death"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports",
          "locator": "The poet, who was 69 years old and suffering from prostate cancer"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0006",
      "statement": "The Nobel Prize in Literature was awarded to him on 21 October 1971, and he received it in Stockholm on 10 December 1971.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after the modern episode's last visit.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "El 21 de octubre le fue concedido el Premio Nobel de Literatura, que recibió en Estocolmo, Suecia, el 10 de diciembre de 1971"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "1971 ... 21 de octubre. Pablo Neruda obtiene el Premio Nobel de Literatura"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "Nobel Prize in Literature 1971"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0007",
      "statement": "He died on 23 September 1973 at the Clínica Santa María in Santiago, aged 69, twelve days after the military coup of 11 September 1973; he had been taken there by ambulance.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after the modern episode.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "El 23 de septiembre de 1973, doce días después del golpe de Estado ... falleció en Santiago en la Clínica Santa María"
        },
        {
          "source_id": "SRC-0006",
          "relationship": "supports",
          "locator": "Neruda was taken by ambulance to the Santa Maria clinic in Santiago where he soon died"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "Fallecimiento: 23 de Septiembre de 1973 Santiago"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0008",
      "statement": "The official cause of death was cancer cachexia: wasting from his prostate cancer. The National Library of Chile's account says he died of prostate cancer.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Records what the death certificate stated; whether it was correct is disputed (CLM-0013).",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports",
          "locator": "The official cause of death was cancer cachexia, involuntary weight and muscle loss that is seen in cancer patients"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports",
          "locator": "The official version was that he died of cachexia, or weakness and wasting of the body due to chronic illness - in this case cancer"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "víctima de un cáncer de próstata"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0009",
      "statement": "His remains were exhumed in 2013. In November 2013 the head of Chile's medical legal service said that no relevant chemical substances had been found that could be linked to his death, and that experts had found traces of medicine used to treat cancer.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after his death; one part of the dispute over the cause of death.",
      "source_links": [
        {
          "source_id": "SRC-0004",
          "relationship": "supports",
          "locator": "No relevant chemical substances have been found that could be linked to Mr. Neruda's death ... found traces of medicine used to treat cancer in Neruda's remains"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports",
          "locator": "Neruda's body was exhumed in 2013 ... those tests showed no toxic agents or poisons in his bone"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0010",
      "statement": "In October 2017 an international panel of 16 forensic experts said it was certain he had not died of cancer cachexia, as the death certificate stated; one member said there was no indication of cachexia and that he was obese at the time of death. The panel said it could neither exclude nor affirm a natural or violent cause of death, and reported potentially deadly bacteria in a sample from one of his molars.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after his death; one part of the dispute over the cause of death. The panel's statement that he was not wasted at death is consistent with a man who was not cachectic; it is not used in the modern episode.",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports",
          "locator": "16-member international panel of forensic experts said they were 100 percent convinced that ... Neruda did not die of cancer ... There was no indication of cachexia. He was an obese man at the time of death"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports",
          "locator": "We still can't exclude nor affirm the natural or violent cause of Pablo Neruda's death"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0011",
      "statement": "In February 2023 laboratories in Canada and Denmark reported DNA of Clostridium botulinum in a molar and in bone fragments sampled in 2015. A member of the work said the finding was not definitive and did not tell what happened; panel members said they could not determine whether he had been poisoned or how the bacterium entered his body.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after his death; the finding is consistent with poisoning but does not prove it, as the scientists said.",
      "source_links": [
        {
          "source_id": "SRC-0007",
          "relationship": "supports",
          "locator": "DNA belonging to Clostridium botulinum in a single molar and in bone fragments ... it's not definitive. It doesn't tell us what happened"
        },
        {
          "source_id": "SRC-0008",
          "relationship": "supports",
          "locator": "inconclusive as to how it entered his system"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0012",
      "statement": "In February 2024 the Santiago appeals court unanimously ordered the investigation into his death reopened, after a judge had declined to do so in December 2023; the death certificate lists cancer.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after his death. No later outcome was found in the sources read.",
      "source_links": [
        {
          "source_id": "SRC-0009",
          "relationship": "supports",
          "locator": "The death of Nobel laureate Pablo Neruda days after Chile's 1973 military coup should be reinvestigated, an appeals court ruled Tuesday ... cancer, which was listed on his death certificate"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0013",
      "statement": "Whether he died of his prostate cancer, of another natural cause such as an infection, or of poisoning is disputed and unresolved. The death certificate gives cancer cachexia; the 2013 tests found no relevant chemical substances; the 2017 panel rejected cachexia without naming a cause; the 2023 finding of Clostridium botulinum could not show how it got there; and the investigation was reopened in 2024.",
      "evidence_grade": "R",
      "certainty": "disputed",
      "clinical_interpretation": "The record takes neither side. The cause of death is not used in the modern episode, which is set two years before his death and does not foreshadow it.",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "disputes",
          "locator": "no relevant chemical substances"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0008",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    }
  ],
  "sources": [
    {
      "source_id": "SRC-0001",
      "title": "Pablo Neruda: Biographical. Nobel Prize in Literature 1971",
      "publisher": "Nobel Prize Outreach (NobelPrize.org)",
      "url": "https://www.nobelprize.org/prizes/literature/1971/neruda/biographical/",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-06",
      "rights_note": "Nobel Foundation biography, from Nobel Lectures; facts and short quotations used with citation."
    },
    {
      "source_id": "SRC-0002",
      "title": "Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias",
      "publisher": "Biblioteca del Congreso Nacional de Chile",
      "url": "https://www.bcn.cl/historiapolitica/resenas_parlamentarias/wiki/Pablo_Neruda",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-06",
      "rights_note": "Library of the National Congress of Chile; facts and short quotations (in Spanish) used with citation."
    },
    {
      "source_id": "SRC-0003",
      "title": "Pablo Neruda (1904-1973). Memoria Chilena",
      "publisher": "Biblioteca Nacional de Chile",
      "url": "https://www.memoriachilena.gob.cl/602/w3-article-3638.html",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-06",
      "rights_note": "National Library of Chile portal; chronology and presentation used with citation (in Spanish)."
    },
    {
      "source_id": "SRC-0004",
      "title": "Forensic tests show no poison in remains of Chilean poet Pablo Neruda (Associated Press)",
      "publisher": "Global News",
      "url": "https://globalnews.ca/news/956510/forensic-tests-show-no-poison-in-remains-of-chilean-poet-pablo-neruda/",
      "source_type": "other",
      "published": "2013-11-08",
      "accessed": "2026-11-06",
      "rights_note": "News report; facts and a short quotation of a public official used with citation."
    },
    {
      "source_id": "SRC-0005",
      "title": "Pablo Neruda did not die of cancer after all, experts say (Associated Press)",
      "publisher": "CBS News",
      "url": "https://www.cbsnews.com/news/pablo-neruda-did-not-die-of-cancer-after-all-experts-say/",
      "source_type": "other",
      "published": "2017-10-20",
      "accessed": "2026-11-06",
      "rights_note": "News report; facts and short quotations of panel members used with citation. Statements by relatives in the report are not used."
    },
    {
      "source_id": "SRC-0006",
      "title": "Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017",
      "publisher": "Smithsonian Magazine",
      "url": "https://www.smithsonianmag.com/smart-news/pablo-neruda-did-not-die-cancer-raising-possibility-he-was-murdered-180966924/",
      "source_type": "other",
      "published": "2017-10-25",
      "accessed": "2026-11-06",
      "rights_note": "Magazine report summarizing the New York Times, NPR and AP; facts and short quotations used with citation."
    },
    {
      "source_id": "SRC-0007",
      "title": "Pablo Neruda died with toxic bacteria in his body, say forensic experts. The Globe and Mail, February 15, 2023",
      "publisher": "The Globe and Mail",
      "url": "https://www.theglobeandmail.com/canada/article-pablo-neruda-died-with-toxic-bacteria-in-his-body-say-forensic",
      "source_type": "other",
      "published": "2023-02-15",
      "accessed": "2026-11-06",
      "rights_note": "News report; facts and a short quotation of a scientist used with citation."
    },
    {
      "source_id": "SRC-0008",
      "title": "Was Neruda poisoned? Probe members say inconclusive (AFP)",
      "publisher": "Hürriyet Daily News",
      "url": "https://hurriyetdailynews.com/was-neruda-poisoned-probe-members-say-inconclusive-180958",
      "source_type": "other",
      "published": "2023-02-18",
      "accessed": "2026-11-06",
      "rights_note": "Wire report; facts and short quotations of scientists used with citation."
    },
    {
      "source_id": "SRC-0009",
      "title": "Death of Chilean poet Pablo Neruda should be reinvestigated, court rules (Associated Press)",
      "publisher": "VPM (NPR News)",
      "url": "https://www.vpm.org/npr-news/2024-02-21/death-of-chilean-poet-pablo-neruda-should-be-reinvestigated-court-rules",
      "source_type": "other",
      "published": "2024-02-21",
      "accessed": "2026-11-06",
      "rights_note": "Wire report; facts used with citation. Statements by a relative in the report are not used."
    },
    {
      "source_id": "SRC-0011",
      "title": "HISTMED Master Roster v3",
      "publisher": "The Human Record project",
      "url": "https://humanrecord.example.org/internal/HISTMED_Master_Roster_v3.xlsx",
      "source_type": "other",
      "published": "2026-11-06",
      "accessed": "2026-11-06",
      "rights_note": "Internal source locator; inherited claims remain provisional until corroborated."
    }
  ],
  "synthetic_episode": {
    "calendar_frame": "modern_shifted",
    "index_date": "2026-06-01",
    "index_age": 66,
    "date_shift_policy": "HR-DATE-SHIFT-1",
    "teaching_objective": "De novo metastatic hormone-sensitive prostate cancer in a 66-year-old Chilean poet and diplomat posted abroad, on the NCCN prostate cancer guideline, the AUA/SUO advanced prostate cancer guideline and the CMID prostate cancer monograph. Urinary symptoms and bone pain with a hard prostate and a raised PSA lead to MRI, an MRI-targeted biopsy, conventional staging (CT and bone scan) and PSMA PET/CT; the disease is classified as low volume, and the choice is continuous androgen deprivation with apalutamide plus radiotherapy to the prostate, without docetaxel. The episode covers flare protection, early PSA response and the three-month PSA, germline and somatic testing, bone health (DXA, FRAX, vitamin D, calcium, exercise, a dental check and denosumab at the osteoporosis dose), the cardiometabolic risks of androgen deprivation, apalutamide's drug interaction with amlodipine, its rash and its effect on thyroid function, hot flashes, sexual health, fatigue, mood, and care in Spanish, his first language, around his writing and diplomatic work. His documented prostate cancer, operated on in France in July 1971 while he was ambassador, frames the episode; the dispute over his death two years later is history only.",
    "visit_schedule": [
      {
        "encounter_id": "ENC-001",
        "date": "2026-06-01",
        "purpose": "New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral"
      },
      {
        "encounter_id": "ENC-002",
        "date": "2026-06-15",
        "purpose": "Two-week review with the medical oncology consultation the same day: biopsy and staging results, the diagnosis, shared decision on treatment, the start of apalutamide, genetic testing, and bone density"
      },
      {
        "encounter_id": "ENC-003",
        "date": "2026-07-13",
        "purpose": "Four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan"
      },
      {
        "encounter_id": "ENC-005",
        "date": "2026-08-10",
        "purpose": "Same-day sick visit for an itchy rash on apalutamide"
      },
      {
        "encounter_id": "ENC-004",
        "date": "2026-09-14",
        "purpose": "Three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year"
      },
      {
        "encounter_id": "ENC-006",
        "date": "2026-10-05",
        "purpose": "Subsequent annual wellness visit"
      }
    ]
  },
  "clinical": {
    "problems": [
      {
        "id": "PRB-001",
        "display": "Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "R97.20",
            "display": "Elevated prostate specific antigen [PSA]",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "abatement_date": "2026-06-15"
      },
      {
        "id": "PRB-002",
        "display": "Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "C61",
            "display": "Malignant neoplasm of prostate",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-06-15"
      },
      {
        "id": "PRB-003",
        "display": "Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "C79.51",
            "display": "Secondary malignant neoplasm of bone",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic metastatic sites.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-06-15"
      },
      {
        "id": "PRB-004",
        "display": "Pelvic lymph node metastases: right external iliac and right obturator nodes",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "C77.5",
            "display": "Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic nodal disease.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-06-15"
      },
      {
        "id": "PRB-005",
        "display": "Hormone-sensitive prostate cancer",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "Z19.1",
            "display": "Hormone sensitive malignancy status",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic status in the modern episode.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-06-15"
      },
      {
        "id": "PRB-006",
        "display": "Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "Z79.899",
            "display": "Other long term (current) drug therapy",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-06-15"
      },
      {
        "id": "PRB-007",
        "display": "Essential hypertension for five years, on amlodipine",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "I10",
            "display": "Essential (primary) hypertension",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-008",
        "display": "Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "E55.9",
            "display": "Vitamin D deficiency, unspecified",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic finding at intake, addressed at the second visit.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-06-15"
      },
      {
        "id": "PRB-009",
        "display": "Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis)",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "M85.89",
            "display": "Other specified disorders of bone density and structure, multiple sites",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone-health finding on the DXA before androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-06-15"
      },
      {
        "id": "PRB-013",
        "display": "Prediabetes (hemoglobin A1c 5.9%)",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "R73.03",
            "display": "Prediabetes",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic finding at intake, relevant to androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-010",
        "display": "Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamide",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "L27.0",
            "display": "Generalized skin eruption due to drugs and medicaments taken internally",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-08-10",
        "abatement_date": "2026-09-14"
      },
      {
        "id": "PRB-011",
        "display": "Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit)",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "Z92.3",
            "display": "Personal history of irradiation",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic: recorded after the course of radiotherapy finished.",
          "author": "The Human Record generator",
          "created": "2026-11-06T16:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-09-14"
      },
      {
        "id": "PRB-012",
        "display": "Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observation",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "R94.6",
            "display": "Abnormal results of thyroid function studies",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic finding; raised TSH is a known effect of apalutamide.",
          "author": "The Human Record generator",
          "created": "2026-11-06T16:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-09-14"
      }
    ],
    "medications": [
      {
        "id": "MED-001",
        "display": "Amlodipine 5 mg oral tablet, one tablet daily",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "197361",
            "display": "amlodipine 5 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet daily"
        },
        "start_date": "2021-04-06",
        "end_date": "2026-07-13",
        "indication_problem_ids": [
          "PRB-007"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic calcium-channel blocker for hypertension for five years; raised to 10 mg at the third visit after apalutamide, a strong CYP3A4 inducer, lowered its effect.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "MED-002",
        "display": "Amlodipine 10 mg oral tablet, one tablet daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "308135",
            "display": "amlodipine 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet daily"
        },
        "start_date": "2026-07-13",
        "indication_problem_ids": [
          "PRB-007"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic dose increase for blood pressure above goal on apalutamide.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "MED-003",
        "display": "Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "198440",
            "display": "acetaminophen 500 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 2,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "Two tablets up to three times daily as needed"
        },
        "start_date": "2026-06-01",
        "end_date": "2026-09-14",
        "indication_problem_ids": [
          "PRB-001",
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic analgesic for bone pain; stopped at the fourth visit when the pain had settled.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "MED-004",
        "display": "Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2630215",
            "display": "apalutamide 240 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet once daily"
        },
        "start_date": "2026-06-15",
        "indication_problem_ids": [
          "PRB-002",
          "PRB-005",
          "PRB-006"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer, started on the consultation day, one week before leuprolide.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "MED-005",
        "display": "Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2606516",
            "display": "leuprolide acetate 22.5 MG Injection",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "intramuscular",
        "frequency": {
          "period": 12,
          "period_unit": "wk",
          "text": "One injection every twelve weeks"
        },
        "start_date": "2026-06-22",
        "indication_problem_ids": [
          "PRB-002",
          "PRB-005",
          "PRB-006"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic continuous androgen deprivation, first dose one week after apalutamide began; the second dose was given at the fourth visit.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "MED-006",
        "display": "Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "801663",
            "display": "cholecalciferol 0.05 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet daily"
        },
        "start_date": "2026-06-15",
        "indication_problem_ids": [
          "PRB-008",
          "PRB-009"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vitamin D repletion before denosumab and androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "MED-007",
        "display": "Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "993452",
            "display": "1 ML denosumab 60 MG/ML Prefilled Syringe",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "subcutaneous",
        "frequency": {
          "period": 26,
          "period_unit": "wk",
          "text": "One injection every six months"
        },
        "start_date": "2026-07-13",
        "indication_problem_ids": [
          "PRB-009"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone-protective drug at the osteoporosis dose, for a FRAX hip fracture risk above 3% on androgen deprivation, after a dental examination; not the monthly dose used for skeletal events in castration-resistant disease.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "MED-008",
        "display": "Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin)",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1014314",
            "display": "triamcinolone acetonide 1 MG/ML Topical Cream",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "topical",
        "frequency": {
          "period": 12,
          "period_unit": "h",
          "text": "Twice daily for two weeks"
        },
        "start_date": "2026-08-10",
        "end_date": "2026-08-24",
        "indication_problem_ids": [
          "PRB-010"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic medium-potency topical steroid for a grade 2 apalutamide rash.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      },
      {
        "id": "MED-009",
        "display": "Cetirizine 10 mg oral tablet, one tablet daily for itch",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1014678",
            "display": "cetirizine hydrochloride 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet daily"
        },
        "start_date": "2026-08-10",
        "end_date": "2026-08-31",
        "indication_problem_ids": [
          "PRB-010"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic non-sedating antihistamine for itch; stopped once the rash faded.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      },
      {
        "id": "MED-010",
        "display": "Atorvastatin 20 mg oral tablet, one tablet daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "617310",
            "display": "atorvastatin 20 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet daily"
        },
        "start_date": "2026-10-05",
        "indication_problem_ids": [
          "PRB-007",
          "PRB-006"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic moderate-intensity statin for primary prevention: 10-year ASCVD risk about 17 percent, with hypertension, prediabetes and androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      }
    ],
    "allergies": [
      {
        "id": "ALG-001",
        "display": "No known allergy",
        "status": "active",
        "assertion": "no_known_allergy",
        "substance": {
          "system": "http://snomed.info/sct",
          "code": "716186003",
          "display": "No known allergy"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic allergy assertion for EHR completeness; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      }
    ],
    "observations": [
      {
        "id": "OBS-PSA-V1",
        "display": "Prostate specific Ag [Mass/volume] in Serum or Plasma",
        "label": "PSA",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 46.8,
        "unit": "ng/mL",
        "reference_range": {
          "high": 4.0
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2857-1",
            "display": "Prostate specific Ag [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic PSA, high, with a hard nodular prostate and bone pain. No PSA or other measurement from his lifetime was found in the sources read.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TESTO-V1",
        "display": "Testosterone [Mass/volume] in Serum or Plasma",
        "label": "Total testosterone",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 468,
        "unit": "ng/dL",
        "reference_range": {
          "low": 264,
          "high": 916,
          "text": "264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2986-8",
            "display": "Testosterone [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic normal testosterone before any treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V1",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 13.6,
        "unit": "g/dL",
        "reference_range": {
          "low": 13.2,
          "high": 16.6
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count at intake; no anemia.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V1",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cell count",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 6.4,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count at intake; no anemia.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V1",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 248,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count at intake; no anemia.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V1",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 139,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V1",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 4.3,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V1",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 104,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "H",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V1",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 0.96,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.74,
          "high": 1.35
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V1",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 87,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CA-V1",
        "display": "Calcium [Mass/volume] in Serum or Plasma",
        "label": "Calcium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 9.6,
        "unit": "mg/dL",
        "reference_range": {
          "low": 8.6,
          "high": 10.3
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "17861-6",
            "display": "Calcium [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V1",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 22,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V1",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 24,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALP-V1",
        "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "Alkaline phosphatase",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 168,
        "unit": "U/L",
        "reference_range": {
          "low": 40,
          "high": 129
        },
        "interpretation": "H",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6768-6",
            "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALB-V1",
        "display": "Albumin [Mass/volume] in Serum or Plasma",
        "label": "Albumin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 4.1,
        "unit": "g/dL",
        "reference_range": {
          "low": 3.5,
          "high": 5.0
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1751-7",
            "display": "Albumin [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at intake: alkaline phosphatase raised; calcium, kidney and liver tests normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-LDH-V1",
        "display": "Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "LDH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 208,
        "unit": "U/L",
        "reference_range": {
          "low": 135,
          "high": 225
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2532-0",
            "display": "Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic LDH at intake; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V1",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 5.9,
        "unit": "%",
        "reference_range": {
          "high": 5.6
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hemoglobin A1c in the prediabetes range.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CHOL-V1",
        "display": "Cholesterol [Mass/volume] in Serum or Plasma",
        "label": "Total cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 214,
        "unit": "mg/dL",
        "reference_range": {
          "high": 199
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2093-3",
            "display": "Cholesterol [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel, not on a statin.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-HDL-V1",
        "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
        "label": "HDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 46,
        "unit": "mg/dL",
        "reference_range": {
          "low": 40
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2085-9",
            "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel, not on a statin.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-LDL-V1",
        "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
        "label": "LDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 140,
        "unit": "mg/dL",
        "reference_range": {
          "high": 129
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "13457-7",
            "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel, not on a statin.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TG-V1",
        "display": "Triglyceride [Mass/volume] in Serum or Plasma",
        "label": "Triglycerides",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 140,
        "unit": "mg/dL",
        "reference_range": {
          "high": 149
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2571-8",
            "display": "Triglyceride [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel, not on a statin.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-VITD-V1",
        "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
        "label": "25-hydroxyvitamin D",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-01",
        "value": 22,
        "unit": "ng/mL",
        "reference_range": {
          "low": 30,
          "high": 100
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "62292-8",
            "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic 25-hydroxyvitamin D below 30 ng/mL.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V1",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-06-01",
        "value": 6,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mild depressive symptoms (worry and poor sleep from pain) at the first visit; below 10. Not a claim about his real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IPSS-V1",
        "display": "International Prostate Symptom Score [IPSS]",
        "label": "IPSS total (0 to 35)",
        "status": "final",
        "effective_date": "2026-06-01",
        "value": 17,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "80976-4",
            "display": "International Prostate Symptom Score [IPSS]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic moderate urinary symptoms.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PAIN-V1",
        "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
        "label": "Pain, 0 to 10",
        "status": "final",
        "effective_date": "2026-06-01",
        "value": 6,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "72514-3",
            "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic pain score for the right hip and low back pain.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-DXAFEM-V2",
        "display": "DXA Femur [T-score] Bone density",
        "label": "Femoral neck T-score (DXA)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-06-15",
        "value": -2.1,
        "unit": "{T-score}",
        "reference_range": {
          "low": -1.0,
          "text": "-1.0 or higher is normal; -2.5 or lower is osteoporosis"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "38263-0",
            "display": "DXA Femur [T-score] Bone density",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic low bone mass at the femoral neck before androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-DXASPINE-V2",
        "display": "DXA Lumbar spine [T-score] Bone density",
        "label": "Lumbar spine T-score, L1 to L4 (DXA)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-06-15",
        "value": -1.4,
        "unit": "{T-score}",
        "reference_range": {
          "low": -1.0,
          "text": "-1.0 or higher is normal; -2.5 or lower is osteoporosis"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "38267-1",
            "display": "DXA Lumbar spine [T-score] Bone density",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic low bone mass at L1 to L4; L5, with a metastasis, is excluded from the analysis.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-V2",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-06-15",
        "value": 1,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-2 on the day of the diagnosis; below 3.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PAIN-V2",
        "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
        "label": "Pain, 0 to 10",
        "status": "final",
        "effective_date": "2026-06-15",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "72514-3",
            "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic pain score on acetaminophen.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PSA-V3",
        "display": "Prostate specific Ag [Mass/volume] in Serum or Plasma",
        "label": "PSA",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 6.2,
        "unit": "ng/mL",
        "reference_range": {
          "high": 4.0
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2857-1",
            "display": "Prostate specific Ag [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic early PSA fall after four weeks of apalutamide and three of leuprolide.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TESTO-V3",
        "display": "Testosterone [Mass/volume] in Serum or Plasma",
        "label": "Total testosterone",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 22,
        "unit": "ng/dL",
        "reference_range": {
          "low": 264,
          "high": 916,
          "text": "264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2986-8",
            "display": "Testosterone [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic castrate testosterone three weeks after leuprolide.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V3",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 140,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V3",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 4.4,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V3",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 101,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "H",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V3",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 0.98,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.74,
          "high": 1.35
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V3",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 85,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CA-V3",
        "display": "Calcium [Mass/volume] in Serum or Plasma",
        "label": "Calcium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 9.3,
        "unit": "mg/dL",
        "reference_range": {
          "low": 8.6,
          "high": 10.3
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "17861-6",
            "display": "Calcium [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V3",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 25,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V3",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 23,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALP-V3",
        "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "Alkaline phosphatase",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 141,
        "unit": "U/L",
        "reference_range": {
          "low": 40,
          "high": 129
        },
        "interpretation": "H",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6768-6",
            "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALB-V3",
        "display": "Albumin [Mass/volume] in Serum or Plasma",
        "label": "Albumin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 4.1,
        "unit": "g/dL",
        "reference_range": {
          "low": 3.5,
          "high": 5.0
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1751-7",
            "display": "Albumin [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry before denosumab: calcium normal; alkaline phosphatase falling.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-VITD-V3",
        "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
        "label": "25-hydroxyvitamin D",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 28,
        "unit": "ng/mL",
        "reference_range": {
          "low": 30,
          "high": 100
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "62292-8",
            "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vitamin D four weeks after starting 2000 units a day; rising.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TSH-V3",
        "display": "Thyrotropin [Units/volume] in Serum or Plasma",
        "label": "TSH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-13",
        "value": 2.4,
        "unit": "m[IU]/L",
        "reference_range": {
          "low": 0.45,
          "high": 4.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3016-3",
            "display": "Thyrotropin [Units/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic TSH; the baseline before apalutamide was missed, so this first value is four weeks into treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-V3",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-07-13",
        "value": 1,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-2.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IPSS-V3",
        "display": "International Prostate Symptom Score [IPSS]",
        "label": "IPSS total (0 to 35)",
        "status": "final",
        "effective_date": "2026-07-13",
        "value": 14,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "80976-4",
            "display": "International Prostate Symptom Score [IPSS]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic urinary symptoms improving on androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PAIN-V3",
        "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
        "label": "Pain, 0 to 10",
        "status": "final",
        "effective_date": "2026-07-13",
        "value": 2,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "72514-3",
            "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic pain score: bone pain much better on androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V5",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cell count",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 6.8,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count at the rash visit: no eosinophilia.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-EOS-V5",
        "display": "Eosinophils [#/volume] in Blood by Automated count",
        "label": "Eosinophils",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 0.3,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 0.0,
          "high": 0.5
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "711-2",
            "display": "Eosinophils [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count at the rash visit: no eosinophilia.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V5",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 0.97,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.74,
          "high": 1.35
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic kidney and liver tests at the rash visit: normal, against a drug reaction with systemic features.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V5",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 86,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic kidney and liver tests at the rash visit: normal, against a drug reaction with systemic features.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V5",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 27,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic kidney and liver tests at the rash visit: normal, against a drug reaction with systemic features.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V5",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 26,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic kidney and liver tests at the rash visit: normal, against a drug reaction with systemic features.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PSA-V4",
        "display": "Prostate specific Ag [Mass/volume] in Serum or Plasma",
        "label": "PSA",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 0.18,
        "unit": "ng/mL",
        "reference_range": {
          "high": 4.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2857-1",
            "display": "Prostate specific Ag [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PSA at three months on androgen deprivation with apalutamide: 0.2 ng/mL or below.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TESTO-V4",
        "display": "Testosterone [Mass/volume] in Serum or Plasma",
        "label": "Total testosterone",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 14,
        "unit": "ng/dL",
        "reference_range": {
          "low": 264,
          "high": 916,
          "text": "264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2986-8",
            "display": "Testosterone [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic castrate testosterone.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V4",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 12.9,
        "unit": "g/dL",
        "reference_range": {
          "low": 13.2,
          "high": 16.6
        },
        "interpretation": "L",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count: mild anemia, expected on androgen deprivation and after radiotherapy.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V4",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cell count",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 5.9,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count: mild anemia, expected on androgen deprivation and after radiotherapy.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V4",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 231,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "panel": {
          "code": "58410-2",
          "display": "CBC panel - Blood by Automated count"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count: mild anemia, expected on androgen deprivation and after radiotherapy.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V4",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 140,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V4",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 4.5,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V4",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 102,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "H",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V4",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 0.99,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.74,
          "high": 1.35
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V4",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 83,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CA-V4",
        "display": "Calcium [Mass/volume] in Serum or Plasma",
        "label": "Calcium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 9.2,
        "unit": "mg/dL",
        "reference_range": {
          "low": 8.6,
          "high": 10.3
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "17861-6",
            "display": "Calcium [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V4",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 24,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V4",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 22,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALP-V4",
        "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "Alkaline phosphatase",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 96,
        "unit": "U/L",
        "reference_range": {
          "low": 40,
          "high": 129
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6768-6",
            "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALB-V4",
        "display": "Albumin [Mass/volume] in Serum or Plasma",
        "label": "Albumin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 4.0,
        "unit": "g/dL",
        "reference_range": {
          "low": 3.5,
          "high": 5.0
        },
        "interpretation": "N",
        "panel": {
          "code": "24323-8",
          "display": "Comprehensive metabolic 2000 panel - Serum or Plasma"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1751-7",
            "display": "Albumin [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic chemistry at three months: alkaline phosphatase normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TSH-V4",
        "display": "Thyrotropin [Units/volume] in Serum or Plasma",
        "label": "TSH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 5.4,
        "unit": "m[IU]/L",
        "reference_range": {
          "low": 0.45,
          "high": 4.5
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3016-3",
            "display": "Thyrotropin [Units/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic TSH raised on apalutamide.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-FT4-V4",
        "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
        "label": "Free T4",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 1.0,
        "unit": "ng/dL",
        "reference_range": {
          "low": 0.8,
          "high": 1.8
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3024-7",
            "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic free T4; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V4",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-14",
        "value": 6.1,
        "unit": "%",
        "reference_range": {
          "high": 5.6
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hemoglobin A1c a little higher after three months of androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-V4",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-09-14",
        "value": 1,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-2.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IPSS-V4",
        "display": "International Prostate Symptom Score [IPSS]",
        "label": "IPSS total (0 to 35)",
        "status": "final",
        "effective_date": "2026-09-14",
        "value": 9,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "80976-4",
            "display": "International Prostate Symptom Score [IPSS]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic urinary symptoms three weeks after prostate radiotherapy.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PAIN-V4",
        "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
        "label": "Pain, 0 to 10",
        "status": "final",
        "effective_date": "2026-09-14",
        "value": 1,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "72514-3",
            "display": "Pain severity - 0-10 verbal numeric rating [Score] - Reported",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic pain score.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-V6",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-10-05",
        "value": 0,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic depression screen at the annual wellness visit.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      },
      {
        "id": "OBS-MINICOG-V6",
        "display": "Total score [Mini-Cog]",
        "label": "Mini-Cog",
        "status": "final",
        "effective_date": "2026-10-05",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "72233-0",
            "display": "Total score [Mini-Cog]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic cognitive screen at the annual wellness visit, also the cognition check on androgen deprivation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      },
      {
        "id": "OBS-AUDITC-V6",
        "display": "Total score [AUDIT-C]",
        "label": "AUDIT-C",
        "status": "final",
        "effective_date": "2026-10-05",
        "value": 2,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "75626-2",
            "display": "Total score [AUDIT-C]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic alcohol screen, low risk; not a claim about his real habits.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      }
    ],
    "procedures": [
      {
        "id": "PROC-001",
        "display": "Multiparametric MRI of the prostate: gland 52 mL; 24 mm PI-RADS 5 lesion in the right peripheral zone from mid-gland to base with extraprostatic extension on the right; no seminal vesicle invasion; 13 mm right external iliac lymph node; abnormal marrow signal in the right iliac bone at the edge of the field",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "719178004",
            "display": "Multiparametric MRI of prostate",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-06-03",
          "end": "2026-06-03"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic imaging at the diagnostic workup.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-002",
        "display": "CT of the chest, abdomen and pelvis with contrast: enlarged right external iliac (13 mm) and right obturator (11 mm) lymph nodes; sclerotic lesions in the right iliac wing and the L5 vertebral body without a soft-tissue mass or canal narrowing; no lung, liver or adrenal lesions",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "433761009",
            "display": "CT of thorax, abdomen and pelvis with contrast",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-06-04",
          "end": "2026-06-04"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic conventional staging.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-003",
        "display": "Whole-body bone scan (technetium-99m): two foci of increased uptake, in the right iliac wing and L5, matching the CT; no other skeletal lesions (fewer than four bone metastases, all in the spine and pelvis: low volume)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "41747008",
            "display": "Radioisotope scan of bone",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-06-04",
          "end": "2026-06-04"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic conventional staging used for the volume classification.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-004",
        "display": "MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+4 (Grade Group 4) in 3 of 3 targeted cores (up to 80 percent of the core) and Gleason 4+4 or 4+3 in 6 of 12 systematic cores, all on the right; 9 of 14 cores in all; perineural invasion present; no intraductal or neuroendocrine features",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "788708005",
            "display": "MRI-US fusion guided transperineal biopsy of prostate",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-06-08",
          "end": "2026-06-08"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic pathology; the sources say he was operated on for prostate cancer in 1971 and give no pathology.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-005",
        "display": "Gallium-68 PSMA PET/CT: intense uptake in the right side of the prostate, in the right external iliac and right obturator nodes, and in the right iliac wing and L5; no other nodal, bone or visceral disease",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "764820005",
            "display": "Positron emission tomography with computed tomography of whole body using gallium-68",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-06-11",
          "end": "2026-06-11"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PSMA staging, concordant with conventional imaging.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-006",
        "display": "Bone densitometry (DXA) of the hip and lumbar spine before androgen deprivation; L5 excluded because of a metastasis",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "312681000",
            "display": "Bone density scan",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-06-15",
          "end": "2026-06-15"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline bone density.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-007",
        "display": "Image-guided intensity-modulated radiotherapy to the prostate, 55 Gy in 20 daily fractions over four weeks, for low-volume metastatic disease; no pelvic nodal or bone radiation",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "441799006",
            "display": "Intensity modulated radiation therapy",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-07-27",
          "end": "2026-08-21"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic radiotherapy to the primary tumor for low-volume metastatic disease, given by radiation oncology.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-008",
        "display": "Advance care planning conversation, about 30 minutes, in Spanish with a professional interpreter, with his consent",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "713603004",
            "display": "Advance care planning",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "period": {
          "start": "2026-10-05",
          "end": "2026-10-05"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic voluntary advance care planning at the annual wellness visit.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      }
    ],
    "immunizations": [
      {
        "id": "IMM-001",
        "display": "Tdap vaccine",
        "status": "completed",
        "date": "2020-09-21",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "115",
            "display": "Tdap",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic adult immunization history in the modern frame; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-002",
        "display": "High-dose influenza vaccine, last season",
        "status": "completed",
        "date": "2025-10-14",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "135",
            "display": "Influenza, high-dose, trivalent, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic adult immunization history in the modern frame; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-003",
        "display": "High-dose influenza vaccine, this season",
        "status": "completed",
        "date": "2026-10-05",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "135",
            "display": "Influenza, high-dose, trivalent, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seasonal influenza vaccination at 65 or older.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      },
      {
        "id": "IMM-004",
        "display": "COVID-19 vaccine, mRNA, this season",
        "status": "completed",
        "date": "2026-10-05",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "309",
            "display": "COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seasonal COVID-19 vaccination at 65 or older.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      },
      {
        "id": "IMM-005",
        "display": "Pneumococcal conjugate vaccine PCV20",
        "status": "completed",
        "date": "2026-10-05",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "216",
            "display": "Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-06"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic single dose for an adult 50 or older with no earlier conjugate vaccine.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      }
    ],
    "family_history": [
      {
        "id": "FH-001",
        "relationship": {
          "system": "http://terminology.hl7.org/CodeSystem/v3-RoleCode",
          "code": "MTH",
          "display": "mother",
          "validation_status": "validated",
          "validated_on": "2026-11-06"
        },
        "condition": "Died shortly after his birth; cause not recorded in the cited source",
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0001"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      }
    ],
    "past_medical_history": [],
    "encounters": [
      {
        "id": "ENC-001",
        "display": "New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral",
        "status": "finished",
        "date": "2026-06-01",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "ENC-002",
        "display": "Two-week review with the medical oncology consultation the same day: biopsy and staging results, the diagnosis, shared decision on treatment, the start of apalutamide, genetic testing, and bone density",
        "status": "finished",
        "date": "2026-06-15",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-06"
        },
        "documentation": {
          "chief_complaint": "Two-week review: biopsy and staging results; medical oncology seen today",
          "hpi": {
            "narrative": "Mr. Neruda returns two weeks after his first visit, with a professional Spanish interpreter. In the past ten days he had an MRI of the prostate, a targeted biopsy at the urology practice, a CT scan, a bone scan and a PSMA PET/CT. The results were explained to him this morning by Dr. Okonkwo-Lund of medical oncology and again today: prostate cancer, Gleason 4+4, that has spread to two lymph nodes in the pelvis and to two places in the bones, the right hip bone and the lowest lumbar vertebra, with nothing in the lungs, liver or other organs. He chose, after hearing the options, to start apalutamide today, with a leuprolide injection in one week and radiotherapy to the prostate in about six weeks. His blood was drawn today for germline genetic testing after counseling. He had his bone density scan this morning. The right hip pain is a little better on acetaminophen, 5 of 10 at worst, and still wakes him some nights; he has no leg weakness, numbness, or change in bladder or bowel control. His urinary symptoms are unchanged. He feels the news is hard but says he would rather know. He wants to keep writing every morning and to continue his duties.",
            "elements": [
              {
                "label": "Diagnosis",
                "value": "Prostate adenocarcinoma, Gleason 4+4 (Grade Group 4), 9 of 14 cores"
              },
              {
                "label": "Staging",
                "value": "Two pelvic lymph nodes and two bone metastases (right ilium, L5); no visceral disease: low volume"
              },
              {
                "label": "Decision",
                "value": "Apalutamide from today, leuprolide in one week, radiotherapy to the prostate; no docetaxel"
              },
              {
                "label": "Starting today",
                "value": "Apalutamide 240 mg daily; cholecalciferol 2000 units daily"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No weight loss, fever or night sweats"
            },
            {
              "system": "Genitourinary",
              "status": "positive",
              "finding": "Frequency, weak stream and nocturia three times, unchanged; no blood in the urine"
            },
            {
              "system": "Musculoskeletal",
              "status": "positive",
              "finding": "Right hip and low back pain, 5 of 10 at worst on acetaminophen"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No leg weakness, numbness or saddle numbness; no change in bladder or bowel control"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Worried but coping; PHQ-2 score 1"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; walks without help, favoring the right hip slightly"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm; blood pressure 142/86 mm Hg; no ankle swelling"
            },
            {
              "system": "Musculoskeletal",
              "finding": "Tender over the right iliac crest; no midline spinal tenderness"
            },
            {
              "system": "Neurological",
              "finding": "Strength 5 of 5 in both legs; sensation and knee and ankle reflexes normal"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Metastatic hormone-sensitive prostate cancer, Grade Group 4, cT3a N1 M1b, low volume",
              "assessment": "De novo metastatic disease, low volume on conventional imaging (two bone metastases, both in the spine and pelvis, and no visceral disease), confirmed by PSMA PET/CT. The plan follows the consultation today: androgen deprivation with an androgen receptor pathway inhibitor, plus radiotherapy to the prostate for low-volume disease. Docetaxel is not added, because its survival benefit is in high-volume disease",
              "plan": [
                "Apalutamide 240 mg once daily from today",
                "Leuprolide 22.5 mg in one week at the oncology clinic, then every twelve weeks; apalutamide started a week before covers the testosterone flare",
                "Radiotherapy to the prostate, 55 Gy in 20 fractions, about six weeks after starting",
                "Germline testing sent today; somatic testing of the biopsy tissue requested"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Bone metastases (right ilium, L5)",
              "assessment": "Pain improving on acetaminophen; no signs of spinal cord compression. Androgen deprivation usually eases bone pain within weeks",
              "plan": [
                "Acetaminophen 1000 mg up to three times a day",
                "Warning signs of cord compression reviewed again in Spanish, with a written card"
              ]
            },
            {
              "problem_id": "PRB-009",
              "display": "Low bone mass before androgen deprivation",
              "assessment": "Femoral neck T-score -2.1 and L1 to L4 -1.4. FRAX, counting androgen deprivation as a cause of secondary osteoporosis, gives a ten-year hip fracture risk of 3.4 percent and a major osteoporotic fracture risk of 13 percent; the hip risk is above the 3 percent threshold for a bone-protective drug",
              "plan": [
                "Dental examination before denosumab",
                "Denosumab 60 mg every six months, the osteoporosis dose, once calcium is confirmed normal and vitamin D is being replaced",
                "Calcium 1000 to 1200 mg a day from food; walking and resistance exercise"
              ]
            },
            {
              "problem_id": "PRB-008",
              "display": "Vitamin D insufficiency",
              "assessment": "25-hydroxyvitamin D 22 ng/mL",
              "plan": [
                "Cholecalciferol 2000 units daily from today; recheck in four weeks before denosumab"
              ]
            },
            {
              "problem_id": "PRB-007",
              "display": "Hypertension",
              "assessment": "142/86 mm Hg, above goal. Apalutamide is a strong CYP3A4 inducer and is expected to lower amlodipine levels",
              "plan": [
                "Blood pressure at the four-week visit; amlodipine dose to be adjusted then"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "PSA before treatment",
              "cadence": "Baseline, then every 3 to 6 months on androgen deprivation",
              "status": "up_to_date",
              "detail": "46.8 ng/mL at the first visit",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Testosterone",
              "cadence": "Baseline, then every 3 to 6 months on androgen deprivation (target below 50 ng/dL)",
              "status": "up_to_date",
              "detail": "468 ng/dL at the first visit",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count, chemistry, alkaline phosphatase and LDH",
              "cadence": "Baseline in metastatic disease",
              "status": "up_to_date",
              "detail": "Hemoglobin 13.6 g/dL; creatinine 0.96 mg/dL; alkaline phosphatase 168 U/L (raised); LDH 208 U/L; calcium 9.6 mg/dL",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "TSH before apalutamide",
              "cadence": "Baseline, then periodically on apalutamide",
              "status": "ordered",
              "detail": "Ordered today before the first dose",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Hemoglobin A1c and lipid panel",
              "cadence": "Baseline and yearly on androgen deprivation",
              "status": "up_to_date",
              "detail": "A1c 5.9 percent and LDL 140 mg/dL at the first visit",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Calcium and 25-hydroxyvitamin D",
              "cadence": "Baseline and periodically on androgen deprivation and bone-protective drugs",
              "status": "up_to_date",
              "detail": "Calcium 9.6 mg/dL and vitamin D 22 ng/mL at the first visit; cholecalciferol starts today",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Bone density (DXA) with FRAX",
              "cadence": "Baseline before androgen deprivation, then every 1 to 2 years",
              "status": "completed_today",
              "detail": "Femoral neck T-score -2.1; L1 to L4 -1.4; FRAX hip 3.4 percent, major osteoporotic 13 percent",
              "observation_ids": [
                "OBS-DXAFEM-V2",
                "OBS-DXASPINE-V2"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Staging: CT, bone scan and PSMA PET/CT",
              "cadence": "At diagnosis",
              "status": "up_to_date",
              "detail": "Completed in the past ten days; low volume on conventional imaging; PSMA PET/CT concordant",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Blood pressure and cardiovascular assessment",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "142/86 mm Hg; no chest pain or breathlessness",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Neurological check for spinal cord compression",
              "cadence": "Every visit with spinal metastases",
              "status": "completed_today",
              "detail": "Normal leg strength, sensation and reflexes; no bladder or bowel change",
              "guideline_ids": [
                "GL-NCCN-PROSTATE-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Distress and depression screen (PHQ-2)",
              "cadence": "At diagnosis and at intervals",
              "status": "completed_today",
              "detail": "PHQ-2 score 1",
              "observation_ids": [
                "OBS-PHQ2-V2"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Pain score",
              "cadence": "Every visit with symptomatic metastases",
              "status": "completed_today",
              "detail": "5 of 10 at worst on acetaminophen, down from 6",
              "observation_ids": [
                "OBS-PAIN-V2"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Urinary symptoms (IPSS)",
              "cadence": "Baseline before treatment, then every follow-up visit",
              "status": "up_to_date",
              "detail": "IPSS 17 at the first visit; unchanged",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Sexual function",
              "cadence": "Baseline before treatment and periodically",
              "status": "completed_today",
              "detail": "Reviewed before androgen deprivation; loss of libido and erections explained",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Cognition",
              "cadence": "Periodically on androgen deprivation",
              "status": "due",
              "detail": "Mini-Cog at the annual wellness visit",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Testosterone flare protection",
              "cadence": "When starting a GnRH agonist with bone metastases",
              "status": "completed_today",
              "detail": "Apalutamide starts today, one week before leuprolide",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Drug interactions with apalutamide",
              "cadence": "When starting and with any new medicine",
              "status": "completed_today",
              "detail": "Strong CYP3A4 inducer: amlodipine levels expected to fall; blood pressure check in four weeks",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Falls and fracture risk on apalutamide",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "No falls; counseled on rugs, lighting and night-time walking",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Medical oncology (genitourinary)",
              "cadence": "Once, then through treatment",
              "status": "completed_today",
              "detail": "Seen today; recommendations in the consultation note",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Germline genetic testing with counseling",
              "cadence": "Once, for metastatic disease",
              "status": "completed_today",
              "detail": "Counseled and blood drawn today; result in two to three weeks",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Radiation oncology for radiotherapy to the prostate",
              "cadence": "Once",
              "status": "ordered",
              "detail": "Planning visit in about four weeks",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-STAMPEDE-H-2018"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Physical activity, calcium intake, no tobacco, and care in Spanish",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Walking as pain allows; calcium from food; written plan in Spanish",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            }
          ],
          "follow_up": "Leuprolide at the oncology clinic in one week. Dental examination before the next visit. Review in four weeks with PSA, testosterone, chemistry, vitamin D and blood pressure",
          "guideline_ids": [
            "GL-NCCN-PROSTATE-2026",
            "GL-AUA-APC-2026",
            "GL-ERLEADA-2026",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-003",
        "display": "Four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan",
        "status": "finished",
        "date": "2026-07-13",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-06"
        },
        "documentation": {
          "chief_complaint": "Four-week review on apalutamide and leuprolide",
          "hpi": {
            "narrative": "Mr. Neruda returns four weeks after starting apalutamide and three weeks after his first leuprolide injection, with a professional Spanish interpreter. The right hip pain has eased to 2 of 10 and no longer wakes him; he takes acetaminophen once a day at most. He gets up to pass urine twice a night instead of three times. Mild hot flashes began last week. His energy is a little lower in the afternoons. He has had no rash, falls, dizziness, leg weakness or numbness. He saw his dentist a week ago; no dental work is needed. He takes vitamin D every day. The germline test result came back last week: no harmful variant was found. He had his radiotherapy planning visit, and treatment starts in two weeks. Before radiotherapy, his bowels are regular, once a day, with no bleeding.",
            "elements": [
              {
                "label": "Treatment",
                "value": "Apalutamide four weeks; leuprolide three weeks ago"
              },
              {
                "label": "Symptoms",
                "value": "Pain 2 of 10; nocturia twice; mild hot flashes; no rash or falls"
              },
              {
                "label": "Results since last visit",
                "value": "Germline panel negative; dental examination clear"
              },
              {
                "label": "Next step",
                "value": "Radiotherapy to the prostate starts in two weeks"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Slightly lower afternoon energy; weight stable"
            },
            {
              "system": "Endocrine",
              "status": "positive",
              "finding": "Mild hot flashes for a week"
            },
            {
              "system": "Musculoskeletal",
              "status": "positive",
              "finding": "Right hip pain 2 of 10"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No rash or itch"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "Bowels regular once a day; no bleeding"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No weakness, numbness or dizziness"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; walks without favoring the right hip"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm; blood pressure 152/90 mm Hg on repeat; no ankle swelling"
            },
            {
              "system": "Skin",
              "finding": "No rash"
            },
            {
              "system": "Neurological",
              "finding": "Strength and sensation normal in both legs"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Metastatic hormone-sensitive prostate cancer on leuprolide and apalutamide",
              "assessment": "Early response: PSA 46.8 to 6.2 ng/mL, testosterone 22 ng/dL (castrate), alkaline phosphatase falling to 141 U/L, and less pain. The germline panel shows no pathogenic variant, so cascade testing of relatives is not needed; somatic testing of the biopsy is pending",
              "plan": [
                "Continue apalutamide 240 mg daily",
                "Radiotherapy to the prostate from two weeks' time",
                "Second leuprolide injection and three-month PSA at the next visit"
              ]
            },
            {
              "problem_id": "PRB-007",
              "display": "Hypertension, higher on apalutamide",
              "assessment": "152/90 mm Hg, up from 142/86, as expected when apalutamide speeds the breakdown of amlodipine",
              "plan": [
                "Amlodipine raised from 5 mg to 10 mg daily",
                "Home blood pressure readings sent through the portal in two weeks"
              ]
            },
            {
              "problem_id": "PRB-009",
              "display": "Low bone mass with high fracture risk",
              "assessment": "Calcium 9.3 mg/dL; vitamin D 28 ng/mL and rising; dental examination clear",
              "plan": [
                "Denosumab 60 mg subcutaneously today, then every six months",
                "Continue cholecalciferol 2000 units daily; report numbness around the mouth or muscle cramps"
              ]
            },
            {
              "problem_id": "PRB-006",
              "display": "Androgen deprivation with apalutamide",
              "assessment": "Mild hot flashes and fatigue. TSH 2.4 mIU/L today; the baseline before apalutamide was not drawn",
              "plan": [
                "TSH every four months on apalutamide",
                "Report any rash early"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "PSA on androgen deprivation",
              "cadence": "Every 3 to 6 months; an early value here for symptomatic disease",
              "status": "completed_today",
              "detail": "6.2 ng/mL, down from 46.8",
              "observation_ids": [
                "OBS-PSA-V3"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Testosterone",
              "cadence": "Every 3 to 6 months on androgen deprivation (target below 50 ng/dL)",
              "status": "completed_today",
              "detail": "22 ng/dL, castrate",
              "observation_ids": [
                "OBS-TESTO-V3"
              ],
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Chemistry with calcium and alkaline phosphatase",
              "cadence": "Before denosumab; periodically in metastatic disease",
              "status": "completed_today",
              "detail": "Calcium 9.3 mg/dL; creatinine 0.98 mg/dL; ALT 25 U/L; alkaline phosphatase 141 U/L, falling",
              "observation_ids": [
                "OBS-NA-V3",
                "OBS-K-V3",
                "OBS-GLU-V3",
                "OBS-CR-V3",
                "OBS-EGFR-V3",
                "OBS-CA-V3",
                "OBS-ALT-V3",
                "OBS-AST-V3",
                "OBS-ALP-V3",
                "OBS-ALB-V3"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "25-hydroxyvitamin D",
              "cadence": "Before a bone-protective drug and periodically",
              "status": "completed_today",
              "detail": "28 ng/mL, up from 22",
              "observation_ids": [
                "OBS-VITD-V3"
              ],
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "TSH on apalutamide",
              "cadence": "Periodically, about every four months",
              "status": "completed_today",
              "detail": "2.4 mIU/L, the first value, four weeks into treatment",
              "observation_ids": [
                "OBS-TSH-V3"
              ],
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Baseline TSH before apalutamide missed",
              "cadence": "Before starting apalutamide",
              "status": "deferred",
              "detail": "Ordered at the last visit but not drawn, a deviation from the protocol: the order was not on the laboratory requisition sent with the germline sample. Today's value is normal, so a pre-existing thyroid problem is unlikely and no harm has resulted, but a true baseline is lost. Corrective action: the apalutamide start checklist now includes TSH, drawn with the first prescription",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Hemoglobin A1c and lipid panel",
              "cadence": "Baseline and yearly on androgen deprivation",
              "status": "up_to_date",
              "detail": "Baseline six weeks ago; A1c again at three months",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Bone density (DXA)",
              "cadence": "Every 1 to 2 years on androgen deprivation",
              "status": "up_to_date",
              "detail": "Baseline four weeks ago",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Blood pressure and cardiovascular assessment",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "152/90 mm Hg, above goal; amlodipine raised",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Neurological check for spinal cord compression",
              "cadence": "Every visit with spinal metastases",
              "status": "completed_today",
              "detail": "Normal",
              "guideline_ids": [
                "GL-NCCN-PROSTATE-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Distress and depression screen (PHQ-2)",
              "cadence": "At intervals",
              "status": "completed_today",
              "detail": "PHQ-2 score 1",
              "observation_ids": [
                "OBS-PHQ2-V3"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Pain score",
              "cadence": "Every visit with symptomatic metastases",
              "status": "completed_today",
              "detail": "2 of 10, down from 6",
              "observation_ids": [
                "OBS-PAIN-V3"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Urinary symptoms (IPSS)",
              "cadence": "Every follow-up visit",
              "status": "completed_today",
              "detail": "IPSS 14, down from 17",
              "observation_ids": [
                "OBS-IPSS-V3"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Bowel function before radiotherapy",
              "cadence": "Baseline before radiotherapy",
              "status": "completed_today",
              "detail": "Regular once a day; no bleeding",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Rash on apalutamide",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "None",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Falls on apalutamide",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "No falls or dizziness",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hot flashes and fatigue",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "Mild; no treatment wanted",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Denosumab: calcium, vitamin D and dental check before the first dose",
              "cadence": "Before each dose",
              "status": "completed_today",
              "detail": "Calcium normal; vitamin D rising; dental examination clear a week ago; first dose given today",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Germline testing result",
              "cadence": "Once",
              "status": "completed_today",
              "detail": "No pathogenic variant on a multigene panel including BRCA1, BRCA2, ATM, CHEK2, PALB2, HOXB13 and the mismatch repair genes",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Somatic tumor testing",
              "cadence": "Once, for metastatic disease",
              "status": "ordered",
              "detail": "Sent on the biopsy tissue; pending",
              "guideline_ids": [
                "GL-AUA-APC-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Radiotherapy to the prostate",
              "cadence": "Once",
              "status": "ordered",
              "detail": "Planning done; 20 fractions start in two weeks",
              "guideline_ids": [
                "GL-STAMPEDE-H-2018"
              ]
            },
            {
              "domain": "survey",
              "measure": "Cognition",
              "cadence": "Periodically on androgen deprivation",
              "status": "due",
              "detail": "Mini-Cog at the annual wellness visit",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Physical activity and calcium intake",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Walking most afternoons; light resistance exercise started; calcium from food",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            }
          ],
          "follow_up": "Radiotherapy from two weeks' time. Home blood pressure readings through the portal in two weeks. Review in nine weeks, at three months, with PSA, testosterone, blood count, chemistry, TSH and hemoglobin A1c, and the second leuprolide injection",
          "guideline_ids": [
            "GL-NCCN-PROSTATE-2026",
            "GL-AUA-APC-2026",
            "GL-ERLEADA-2026",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-004",
        "display": "Three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year",
        "status": "finished",
        "date": "2026-09-14",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-06"
        },
        "documentation": {
          "chief_complaint": "Three-month review on androgen deprivation with apalutamide, after radiotherapy to the prostate",
          "hpi": {
            "narrative": "Mr. Neruda returns three months after starting treatment, with a professional Spanish interpreter. He finished 20 fractions of radiotherapy to the prostate three weeks ago. During the last two weeks of treatment he had more frequent urination and looser stools, and both are settling: he now gets up once a night, and his bowels are once or twice a day, with no bleeding. The rash he had five weeks ago faded within two weeks on the cream and cetirizine, and he has stopped both. The hip pain has gone; he has not taken acetaminophen for three weeks. Hot flashes come four or five times a day. His weight is up 2 kg, and he tires in the afternoons but still walks daily and writes every morning. He has had no falls. His home blood pressure readings have been around 130/80 since the amlodipine increase. He asks whether the treatment is working.",
            "elements": [
              {
                "label": "Radiotherapy",
                "value": "55 Gy in 20 fractions, finished three weeks ago"
              },
              {
                "label": "Urinary and bowel",
                "value": "Nocturia once; stools once or twice a day, settling; no bleeding"
              },
              {
                "label": "Rash",
                "value": "Resolved; triamcinolone and cetirizine stopped"
              },
              {
                "label": "Pain",
                "value": "None; acetaminophen stopped three weeks ago"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Afternoon fatigue; weight up 2 kg"
            },
            {
              "system": "Endocrine",
              "status": "positive",
              "finding": "Hot flashes four or five times a day; no cold intolerance or constipation"
            },
            {
              "system": "Genitourinary",
              "status": "positive",
              "finding": "Nocturia once; no burning or blood"
            },
            {
              "system": "Gastrointestinal",
              "status": "positive",
              "finding": "Softer stools once or twice a day, settling; no bleeding"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "Rash gone"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No bone pain"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm; blood pressure 132/80 mm Hg; no ankle swelling"
            },
            {
              "system": "Neck",
              "finding": "Thyroid not enlarged"
            },
            {
              "system": "Skin",
              "finding": "No rash; mild darkening of the skin over the radiotherapy field"
            },
            {
              "system": "Neurological",
              "finding": "Strength and sensation normal in both legs"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Metastatic hormone-sensitive prostate cancer, three months on treatment",
              "assessment": "Good response: PSA 0.18 ng/mL, at or below 0.2 ng/mL, which predicts a better outcome; testosterone 14 ng/dL; alkaline phosphatase back to normal at 96 U/L. Somatic testing of the biopsy found no alteration in the homologous recombination repair genes, and the tumor is microsatellite stable",
              "plan": [
                "Second leuprolide 22.5 mg injection today",
                "Continue apalutamide 240 mg daily",
                "PSA and testosterone every three months; imaging if PSA rises or new symptoms appear"
              ]
            },
            {
              "problem_id": "PRB-011",
              "display": "After radiotherapy to the prostate",
              "assessment": "Grade 1 urinary and bowel effects, settling. IPSS 9, down from 17 before treatment",
              "plan": [
                "Report blood in the urine or stool at any time"
              ]
            },
            {
              "problem_id": "PRB-012",
              "display": "Raised TSH on apalutamide",
              "assessment": "TSH 5.4 mIU/L with free T4 1.0 ng/dL: subclinical, without symptoms of hypothyroidism. Raised TSH is common on apalutamide",
              "plan": [
                "Repeat TSH and free T4 with the lipid panel in about eight weeks; levothyroxine if free T4 falls or TSH rises above 10"
              ]
            },
            {
              "problem_id": "PRB-006",
              "display": "Androgen deprivation with apalutamide",
              "assessment": "Hemoglobin 12.9 g/dL, mildly low, as expected; hemoglobin A1c 6.1 percent, up from 5.9; weight up 2 kg; hot flashes four or five times a day",
              "plan": [
                "Walking and resistance exercise; fewer sweets at official dinners",
                "Lipids and the statin decision at the annual wellness visit in three weeks"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Bone metastases",
              "assessment": "Pain resolved",
              "plan": [
                "Acetaminophen stopped"
              ]
            },
            {
              "problem_id": "PRB-010",
              "display": "Apalutamide rash",
              "assessment": "Resolved without stopping apalutamide",
              "plan": [
                "No treatment needed"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "PSA on androgen deprivation",
              "cadence": "Every 3 to 6 months",
              "status": "completed_today",
              "detail": "0.18 ng/mL at three months",
              "observation_ids": [
                "OBS-PSA-V4"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Testosterone",
              "cadence": "Every 3 to 6 months on androgen deprivation (target below 50 ng/dL)",
              "status": "completed_today",
              "detail": "14 ng/dL, castrate",
              "observation_ids": [
                "OBS-TESTO-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count",
              "cadence": "Periodically in metastatic disease",
              "status": "completed_today",
              "detail": "Hemoglobin 12.9 g/dL (mildly low); white cells and platelets normal",
              "observation_ids": [
                "OBS-HGB-V4",
                "OBS-WBC-V4",
                "OBS-PLT-V4"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Chemistry with calcium and alkaline phosphatase",
              "cadence": "Periodically on denosumab and in metastatic disease",
              "status": "completed_today",
              "detail": "Calcium 9.2 mg/dL; creatinine 0.99 mg/dL; alkaline phosphatase 96 U/L, normal",
              "observation_ids": [
                "OBS-NA-V4",
                "OBS-K-V4",
                "OBS-GLU-V4",
                "OBS-CR-V4",
                "OBS-EGFR-V4",
                "OBS-CA-V4",
                "OBS-ALT-V4",
                "OBS-AST-V4",
                "OBS-ALP-V4",
                "OBS-ALB-V4"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "TSH and free T4 on apalutamide",
              "cadence": "About every four months",
              "status": "completed_today",
              "detail": "TSH 5.4 mIU/L (raised); free T4 1.0 ng/dL (normal)",
              "observation_ids": [
                "OBS-TSH-V4",
                "OBS-FT4-V4"
              ],
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Hemoglobin A1c",
              "cadence": "Baseline and yearly on androgen deprivation; repeated at three months for prediabetes",
              "status": "completed_today",
              "detail": "6.1 percent, up from 5.9",
              "observation_ids": [
                "OBS-A1C-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Lipid panel",
              "cadence": "Baseline and yearly on androgen deprivation",
              "status": "up_to_date",
              "detail": "Baseline at the first visit; statin decision at the annual wellness visit",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Bone density (DXA)",
              "cadence": "Every 1 to 2 years on androgen deprivation",
              "status": "up_to_date",
              "detail": "Baseline three months ago",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Restaging imaging",
              "cadence": "If PSA rises or symptoms appear",
              "status": "not_indicated",
              "detail": "PSA 0.18 ng/mL and no symptoms",
              "guideline_ids": [
                "GL-AUA-APC-2026",
                "GL-NCCN-PROSTATE-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Blood pressure and cardiovascular assessment",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "132/80 mm Hg on amlodipine 10 mg; home readings about 130/80",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Neurological check for spinal cord compression",
              "cadence": "Every visit with spinal metastases",
              "status": "completed_today",
              "detail": "Normal",
              "guideline_ids": [
                "GL-NCCN-PROSTATE-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Distress and depression screen (PHQ-2)",
              "cadence": "At intervals",
              "status": "completed_today",
              "detail": "PHQ-2 score 1",
              "observation_ids": [
                "OBS-PHQ2-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Pain score",
              "cadence": "Every visit with symptomatic metastases",
              "status": "completed_today",
              "detail": "1 of 10",
              "observation_ids": [
                "OBS-PAIN-V4"
              ],
              "guideline_ids": [
                "GL-AUA-APC-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Urinary symptoms (IPSS)",
              "cadence": "Every follow-up visit, particularly after radiotherapy",
              "status": "completed_today",
              "detail": "IPSS 9, down from 17",
              "observation_ids": [
                "OBS-IPSS-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Bowel function after radiotherapy",
              "cadence": "Every visit after radiotherapy",
              "status": "completed_today",
              "detail": "Softer stools once or twice a day, settling; no bleeding",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Sexual function",
              "cadence": "Periodically on androgen deprivation",
              "status": "completed_today",
              "detail": "Lower libido and erections, as expected; no treatment wanted now",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            },
            {
              "domain": "survey",
              "measure": "Cognition",
              "cadence": "Periodically on androgen deprivation",
              "status": "due",
              "detail": "Mini-Cog at the annual wellness visit in three weeks",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Rash on apalutamide",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "Resolved",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Falls on apalutamide",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "No falls",
              "guideline_ids": [
                "GL-ERLEADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hot flashes and fatigue",
              "cadence": "Every visit on androgen deprivation",
              "status": "completed_today",
              "detail": "Hot flashes four or five times a day; afternoon fatigue; no medicine wanted yet",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Second leuprolide injection",
              "cadence": "Every twelve weeks",
              "status": "completed_today",
              "detail": "Given today",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Somatic tumor testing result",
              "cadence": "Once",
              "status": "completed_today",
              "detail": "No homologous recombination repair alteration; microsatellite stable",
              "guideline_ids": [
                "GL-AUA-APC-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Physical activity, weight and calcium intake",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Walking daily; resistance exercise twice a week; calcium from food",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ACS-PCA-SURV-2014"
              ]
            }
          ],
          "follow_up": "Annual wellness visit in three weeks. TSH and free T4 in about eight weeks. Medical oncology and the third leuprolide injection in twelve weeks, with PSA and testosterone. Denosumab again in four months",
          "guideline_ids": [
            "GL-NCCN-PROSTATE-2026",
            "GL-AUA-APC-2026",
            "GL-ERLEADA-2026",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-005",
        "display": "Same-day sick visit for an itchy rash on apalutamide",
        "status": "finished",
        "date": "2026-08-10",
        "visit_type": "sick",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "185345009",
          "display": "Encounter for symptom",
          "validation_status": "validated",
          "validated_on": "2026-11-06"
        },
        "documentation": {
          "chief_complaint": "Itchy rash for four days",
          "billing_note": "Problem-oriented office visit, established patient",
          "hpi": {
            "narrative": "Mr. Neruda, a 67-year-old man with metastatic hormone-sensitive prostate cancer on leuprolide and apalutamide, now in the third week of radiotherapy to the prostate, called the clinic and was seen the same day, with a professional Spanish interpreter. Four days ago an itchy red rash appeared on his chest and spread to his back and upper arms. He has taken apalutamide for eight weeks. He started no other new medicine, soap or detergent. He has no fever, sore mouth, sore or red eyes, blisters, peeling, swelling of the face, or joint pain. The skin over the radiotherapy field on his lower abdomen is not affected. The itch keeps him awake for part of the night, but he is still writing every morning.",
            "elements": [
              {
                "label": "Onset",
                "value": "Four days ago, eight weeks after starting apalutamide"
              },
              {
                "label": "Location",
                "value": "Chest, back and upper arms; face, palms, soles and the radiotherapy field spared"
              },
              {
                "label": "Character",
                "value": "Red, flat and slightly raised spots joining into patches; itchy"
              },
              {
                "label": "Associated signs and symptoms",
                "value": "Denies fever, mouth or eye sores, blisters, peeling and facial swelling"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever or chills; tiredness from radiotherapy, unchanged"
            },
            {
              "system": "Integumentary",
              "status": "positive",
              "finding": "Itchy rash on the trunk and upper arms; no blisters or peeling"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No redness, pain or discharge"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "negative",
              "finding": "No mouth sores or sore throat"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No joint pain or swelling; no bone pain"
            },
            {
              "system": "Genitourinary",
              "status": "positive",
              "finding": "Urinary frequency during radiotherapy, as expected; no burning or blood"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well, comfortable; temperature 36.8, blood pressure 136/82, pulse 80"
            },
            {
              "system": "Skin",
              "finding": "Blanching erythematous macules and papules, merging into patches, over the chest, abdomen above the radiotherapy field, back and upper arms, about 20 percent of body surface; no vesicles, bullae, target lesions, skin pain or Nikolsky sign; face, palms, soles and genitals clear"
            },
            {
              "system": "Eyes",
              "finding": "Conjunctivae clear"
            },
            {
              "system": "Mouth",
              "finding": "Mucosa moist and intact; no ulcers"
            },
            {
              "system": "Lymph nodes",
              "finding": "No cervical, axillary or inguinal lymphadenopathy"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender; no liver enlargement"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-010",
              "display": "Apalutamide rash, grade 2",
              "assessment": "A maculopapular drug rash, a common effect of apalutamide, covering about 20 percent of the skin: grade 2 (10 to 30 percent). No features of a severe reaction: no mucosal sores, blisters or skin pain, no fever, no lymph nodes, eosinophils 0.3, and normal liver and kidney tests (ALT 27, AST 26, creatinine 0.97). Grade 2 rash does not require stopping apalutamide, and most such rashes settle on topical treatment",
              "plan": [
                "Continue apalutamide 240 mg daily",
                "Triamcinolone 0.1% cream twice daily for two weeks to the rash, not the face or groin, and a fragrance-free emollient",
                "Cetirizine 10 mg daily for itch",
                "Stop apalutamide and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skin",
                "Medical oncology informed today; radiotherapy continues"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Metastatic hormone-sensitive prostate cancer",
              "assessment": "Third week of radiotherapy to the prostate; urinary frequency as expected; no bone pain",
              "plan": [
                "Three-month review as planned in five weeks"
              ]
            }
          ],
          "follow_up": "Nurse telephone call in three days, with a photograph of the rash through the patient portal if he wishes. Three-month review in five weeks. Same-day review for any of the warning signs",
          "guideline_ids": [
            "GL-ERLEADA-2026",
            "GL-NCCN-PROSTATE-2026"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic unscheduled sick visit; the illness is not a historical claim.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      },
      {
        "id": "ENC-006",
        "display": "Subsequent annual wellness visit",
        "status": "finished",
        "date": "2026-10-05",
        "visit_type": "annual_wellness_subsequent",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "281038008",
          "display": "Geriatric annual health check",
          "validation_status": "validated",
          "validated_on": "2026-11-06"
        },
        "documentation": {
          "chief_complaint": "Subsequent annual wellness visit; no new complaints",
          "billing_note": "HCPCS G0439 (subsequent annual wellness visit) with CPT 99497 (advance care planning), both on the same day",
          "hpi": {
            "narrative": "Mr. Neruda returns for his subsequent annual wellness visit, with a professional Spanish interpreter; his first was with his previous physician last year. He completed the health risk assessment in Spanish beforehand. He is three weeks past his second leuprolide injection and continues apalutamide; radiotherapy to the prostate finished six weeks ago. The rash has gone. Hot flashes come four or five times a day and wake him once or twice a night; he would rather not take a medicine for them yet. His energy is lower in the afternoons, and he rests after lunch. He has no bone pain, has had no falls, and walks most afternoons. He writes every morning and has kept his official duties, apart from a week of engagements put off during radiotherapy. His interest in sex has fallen, as he was told it might; he has thought about it and does not want treatment for it now.",
            "elements": [
              {
                "label": "Visit",
                "value": "Subsequent annual wellness visit"
              },
              {
                "label": "Safety events",
                "value": "No falls, emergency visits or hospital stays in the past year; one sick visit for a drug rash"
              },
              {
                "label": "Medicines",
                "value": "Leuprolide 22.5 mg every twelve weeks; apalutamide 240 mg daily; amlodipine 10 mg daily; cholecalciferol 2000 units daily; denosumab 60 mg every six months"
              },
              {
                "label": "Active conditions",
                "value": "Metastatic hormone-sensitive prostate cancer on androgen deprivation with apalutamide; hypertension; prediabetes; low bone mass"
              },
              {
                "label": "Functional status",
                "value": "Independent in all activities and instrumental activities of daily living"
              }
            ]
          },
          "health_risk_assessment": [
            {
              "domain": "Self-rated health",
              "finding": "Fair to good"
            },
            {
              "domain": "Psychosocial",
              "finding": "Writing every morning; close to his wife and friends; worry about the cancer at times, manageable"
            },
            {
              "domain": "Tobacco",
              "finding": "Never used tobacco"
            },
            {
              "domain": "Alcohol and drugs",
              "finding": "Wine with dinner a few evenings a week (AUDIT-C 2); no other drug use"
            },
            {
              "domain": "Physical activity",
              "finding": "Walks 30 minutes most afternoons; light resistance exercise twice a week, begun for bone and muscle on androgen deprivation"
            },
            {
              "domain": "Nutrition",
              "finding": "Many official dinners; dairy, fish and greens for calcium; weight up 2.2 kg since starting treatment"
            },
            {
              "domain": "Sleep",
              "finding": "Hot flashes wake him once or twice a night; rests after lunch"
            },
            {
              "domain": "Activities of daily living",
              "finding": "Independent"
            },
            {
              "domain": "Instrumental activities of daily living",
              "finding": "Independent; manages his own medicines with a weekly pill box"
            },
            {
              "domain": "Home safety",
              "finding": "Smoke detectors working; rugs secured; good lighting on the stairs"
            },
            {
              "domain": "Falls",
              "finding": "No falls; no fear of falling"
            },
            {
              "domain": "Hearing and vision",
              "finding": "Reading glasses; eye examination last year; hearing good"
            },
            {
              "domain": "Memory",
              "finding": "No concerns"
            },
            {
              "domain": "Pain",
              "finding": "None"
            }
          ],
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Lower afternoon energy on androgen deprivation; weight up 2.2 kg; no fever or night sweats"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No change in vision"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "negative",
              "finding": "No hearing change; no mouth sores"
            },
            {
              "system": "Cardiovascular",
              "status": "negative",
              "finding": "No chest pain, palpitations or leg swelling"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough or breathlessness"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "Bowels back to normal after radiotherapy; no bleeding"
            },
            {
              "system": "Genitourinary",
              "status": "positive",
              "finding": "Nocturia once; stream better; lower libido and erections"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No bone or joint pain"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "Rash resolved"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No weakness, numbness or unsteadiness"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood steady; PHQ-2 score 0"
            },
            {
              "system": "Endocrine",
              "status": "positive",
              "finding": "Hot flashes four or five times a day; no breast tenderness"
            }
          ],
          "exam": [
            {
              "system": "Constitutional",
              "finding": "Well and engaged; weight 94.6 kg, BMI 29.9; blood pressure 128/78"
            },
            {
              "system": "Eyes",
              "finding": "Near vision 20/30 with reading glasses"
            },
            {
              "system": "Ears",
              "finding": "Whispered-voice test passed on both sides"
            },
            {
              "system": "Neck",
              "finding": "No thyroid enlargement; no lymph nodes"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm at 70 per minute; no murmur; no ankle swelling"
            },
            {
              "system": "Respiratory",
              "finding": "Clear"
            },
            {
              "system": "Chest",
              "finding": "Mild gynecomastia without tenderness"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender"
            },
            {
              "system": "Musculoskeletal",
              "finding": "No spinal or pelvic tenderness; Timed Up and Go 9 seconds; rises from a chair without using his arms"
            },
            {
              "system": "Neurological",
              "finding": "Strength and sensation normal in the legs; gait steady; Mini-Cog 5 of 5"
            },
            {
              "system": "Psychiatric",
              "finding": "Euthymic, thoughtful; judgment and insight intact"
            },
            {
              "system": "Skin",
              "finding": "Rash resolved without scarring; no suspicious lesions"
            }
          ],
          "assessment_plan": [
            {
              "display": "Subsequent annual wellness visit completed",
              "assessment": "Health risk assessment reviewed and a written prevention plan given in Spanish. Depression, alcohol, cognitive and fall-risk screens are negative. On the lipid panel from the first visit (total cholesterol 214, HDL 46, LDL 140 mg/dL), with treated blood pressure and no smoking or diabetes, the 10-year ASCVD risk by the pooled cohort equations is about 17 percent; androgen deprivation adds cardiometabolic risk",
              "plan": [
                "Atorvastatin 20 mg daily after shared decision; lipid panel and ALT in six weeks, with the TSH and free T4 repeat",
                "Next annual wellness visit in one year"
              ]
            },
            {
              "problem_id": "PRB-006",
              "display": "Androgen deprivation with apalutamide",
              "assessment": "Hot flashes, afternoon fatigue, weight gain of 2.2 kg and lower libido, all expected; mild gynecomastia; no falls; cognition normal",
              "plan": [
                "Keep walking and resistance exercise, which help fatigue, weight, muscle and bone",
                "Venlafaxine or gabapentin are available for hot flashes if he wants them",
                "Sexual health: the cancer center's sexual health clinic is open to him, alone or with his wife, whenever he wishes"
              ]
            },
            {
              "problem_id": "PRB-007",
              "display": "Hypertension",
              "assessment": "128/78 mm Hg on amlodipine 10 mg; at goal",
              "plan": [
                "Continue amlodipine 10 mg daily"
              ]
            }
          ],
          "prevention_plan": [
            {
              "service": "Influenza vaccine",
              "status": "completed_today",
              "detail": "High-dose vaccine given today",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "COVID-19 vaccine",
              "status": "completed_today",
              "detail": "This season's vaccine given today",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Pneumococcal vaccine",
              "status": "completed_today",
              "detail": "PCV20 given today; no earlier pneumococcal vaccine; no further doses needed",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Recombinant zoster vaccine",
              "status": "due",
              "detail": "Never given; dose 1 at the next visit, as he wanted no more than three injections today",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "RSV vaccine",
              "status": "not_indicated",
              "detail": "Under 75 without a chronic heart, lung, kidney or immune condition that raises his risk; to be reviewed at 75 or if that changes",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Tetanus, diphtheria and pertussis booster",
              "status": "up_to_date",
              "detail": "Tdap six years ago; next in four years",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Colorectal cancer screening",
              "status": "up_to_date",
              "detail": "Normal colonoscopy seven years ago; next due in three years",
              "guideline_ids": [
                "GL-USPSTF-CRC-2021"
              ]
            },
            {
              "service": "Abdominal aortic aneurysm screening",
              "status": "not_indicated",
              "detail": "Recommended for men 65 to 75 who have ever smoked; he never smoked",
              "guideline_ids": [
                "GL-USPSTF-AAA-2019"
              ]
            },
            {
              "service": "Lung cancer screening",
              "status": "not_indicated",
              "detail": "Never smoker"
            },
            {
              "service": "Hepatitis C screening",
              "status": "up_to_date",
              "detail": "One-time screening negative eight years ago",
              "guideline_ids": [
                "GL-USPSTF-HCV-2020"
              ]
            },
            {
              "service": "Cholesterol and statin decision",
              "status": "completed_today",
              "detail": "10-year ASCVD risk about 17 percent; atorvastatin 20 mg started after discussion",
              "guideline_ids": [
                "GL-USPSTF-STATIN-2022",
                "GL-CMID-2026"
              ]
            },
            {
              "service": "Diabetes screening",
              "status": "up_to_date",
              "detail": "Hemoglobin A1c 6.1 percent three weeks ago (prediabetes); repeat yearly on androgen deprivation",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "service": "Bone density",
              "status": "up_to_date",
              "detail": "DXA four months ago; denosumab every six months; repeat DXA in one to two years",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "service": "Depression screening",
              "status": "completed_today",
              "detail": "PHQ-2 score 0"
            },
            {
              "service": "Unhealthy alcohol use screening",
              "status": "completed_today",
              "detail": "AUDIT-C score 2, low risk"
            },
            {
              "service": "Cognitive assessment",
              "status": "completed_today",
              "detail": "Mini-Cog 5 of 5"
            },
            {
              "service": "Falls prevention",
              "status": "completed_today",
              "detail": "Timed Up and Go 9 seconds; no falls; apalutamide raises fall risk, so resistance and balance exercise continue",
              "guideline_ids": [
                "GL-USPSTF-FALLS-2024",
                "GL-ERLEADA-2026"
              ]
            },
            {
              "service": "Skin check",
              "status": "completed_today",
              "detail": "No suspicious lesions"
            }
          ],
          "advance_care_planning": "Voluntary advance care planning discussion of about 30 minutes, in Spanish with a professional interpreter, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is to keep writing, to be told the truth about his illness in his own language, and to make his own decisions. He chose not to record specific treatment preferences today and will review the plan with his oncologist and with this clinic yearly or if his health changes.",
          "follow_up": "Zoster vaccine dose 1 and blood pressure check in six weeks, with a lipid panel, ALT, TSH and free T4. Medical oncology and the next leuprolide injection in nine weeks. Next annual wellness visit in one year",
          "guideline_ids": [
            "GL-AWV-CMS",
            "GL-PREV-2026",
            "GL-CDC-IMZ-2026",
            "GL-USPSTF-STATIN-2022",
            "GL-CMID-2026"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic Medicare-style annual wellness visit in the modern episode.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      }
    ],
    "vital_sign_sets": [
      {
        "id": "VSET-001",
        "date": "2026-06-01",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 92.4,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 29.2,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 146,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 88,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 76,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs, average of two readings after five minutes' rest. No measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-002",
        "date": "2026-06-15",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 92.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 29.0,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 142,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 86,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 74,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs, average of two readings after five minutes' rest. No measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-003",
        "date": "2026-07-13",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 92.8,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 29.3,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 152,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 90,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 76,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs, average of two readings after five minutes' rest. No measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-004",
        "date": "2026-08-10",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 93.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 29.4,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 136,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 82,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 80,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.8,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs, average of two readings after five minutes' rest. No measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-005",
        "date": "2026-09-14",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 94.2,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 29.7,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 132,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 80,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 72,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs, average of two readings after five minutes' rest. No measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-006",
        "date": "2026-10-05",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 94.6,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 29.9,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 128,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 78,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 70,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs at the annual wellness visit, average of two readings.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        }
      }
    ],
    "social_history": [
      {
        "id": "SOC-001",
        "display": "Poet and diplomat: Chile's ambassador, posted abroad, with a full schedule of official duties; writes poetry every morning and is at work on a new collection",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0003"
          ],
          "synthetic_reason": "Synthetic modern occupation anchored to his documented career as a poet and as ambassador to France.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-002",
        "display": "Language: Spanish is his first language; fluent in French. A professional Spanish medical interpreter is used for every major discussion, with written materials in Spanish; he asked to be called Mr. Neruda",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic language and communication plan in the modern episode.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-003",
        "display": "Tobacco: never. Alcohol: wine with dinner a few evenings a week (AUDIT-C 2). No drug use",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic substance history; not a claim about his real habits.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-004",
        "display": "Lives with his wife in the official residence; she is not named, is given no role in his care, and is not a source of history",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic household description; no relative is named or given a role in his care.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-005",
        "display": "Activity: walks in the city most afternoons; many official dinners each week",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic activity and diet history.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-006",
        "display": "Insurance: an international health plan through his country's diplomatic service; the clinic documents his care with its usual U.S. conventions",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic coverage statement recording the care-setting decision.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-007",
        "display": "Strengths: a lifetime of disciplined daily writing, curiosity, a wide circle of friends, and an ease with hard conversations",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003"
          ],
          "synthetic_reason": "Synthetic strengths anchored to his documented life as a writer.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      }
    ],
    "functional_status": [
      {
        "id": "FUNC-001",
        "display": "Independent in all daily activities; walking limited to about 20 minutes by right hip pain; ECOG performance status 1",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic functional status for the presenting pain.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      }
    ],
    "mental_status": [
      {
        "id": "MSE-001",
        "display": "Alert, articulate and warm; worried about what the pain means; sleep broken by pain and nocturia; PHQ-9 score 6",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding; not a claim about his real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      }
    ],
    "consultation": {
      "referral": {
        "question": "Man of 66 with four months of urinary symptoms and six weeks of right hip and low back pain, a hard nodular prostate, PSA 46.8 ng/mL and a raised alkaline phosphatase: suspected metastatic prostate cancer. Please confirm the diagnosis and extent and advise on treatment, including bone health and genetic testing",
        "urgency": "Urgent, within two weeks",
        "pertinent_history": "Poet and diplomat, posted abroad; Spanish is his first language and a professional interpreter is used. Four months of frequency, weak stream and nocturia three times (IPSS 17); six weeks of aching right buttock and hip pain and low back pain, worse at night, pain 6 of 10. No leg weakness, numbness, or change in bladder or bowel control. Digital rectal examination: hard, nodular right lobe with loss of the right lateral border. Hypertension for five years on amlodipine 5 mg; blood pressure 146/88 mm Hg today. Never smoker. Laboratory tests today: PSA 46.8 ng/mL, testosterone 468 ng/dL, hemoglobin 13.6 g/dL, creatinine 0.96 mg/dL, calcium 9.6 mg/dL, alkaline phosphatase 168 U/L, LDH 208 U/L, hemoglobin A1c 5.9 percent, LDL 140 mg/dL, 25-hydroxyvitamin D 22 ng/mL. PHQ-9 score 6. MRI of the prostate, a targeted biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan and PSMA PET/CT are being arranged before your visit. Acetaminophen started for pain",
        "questions": [
          "Do the results confirm prostate cancer, and what is the extent and volume of disease?",
          "Which systemic treatment do you recommend, and is docetaxel indicated?",
          "Is radiotherapy to the prostate indicated?",
          "How should bone health and the bone metastases be managed, including the need for a bone-protective drug and at what dose?",
          "Should he have germline and tumor genetic testing?",
          "How will the treatment interact with his amlodipine, and which monitoring should primary care carry out?"
        ]
      },
      "consultant_note": {
        "history": "Mr. Neruda is seen at the request of Dr. Fairweather-Diaz, with a professional Spanish interpreter, for suspected metastatic prostate cancer. He has had four months of urinary frequency, a weak stream and nocturia, and six weeks of right hip and low back pain, now 5 of 10 on acetaminophen. He has no leg weakness, numbness, or change in bladder or bowel control, and no weight loss. He has hypertension treated with amlodipine and no other illness. He never smoked. Beyond his mother's death shortly after his birth, he does not know his family's medical history. He is fully active apart from the hip pain (ECOG 1), writes every morning and carries a full schedule of official duties. He asked for a plain account of the results and of every option",
        "data_reviewed": "Multiparametric MRI of the prostate (52 mL gland; 24 mm PI-RADS 5 right peripheral zone lesion with extraprostatic extension; 13 mm right external iliac node); MRI-targeted biopsy (Gleason 4+4, Grade Group 4, in 9 of 14 cores, all on the right, with perineural invasion); CT of the chest, abdomen and pelvis (right external iliac 13 mm and obturator 11 mm nodes; sclerotic lesions in the right iliac wing and L5 without canal narrowing; no visceral disease); bone scan (two lesions only, right ilium and L5); gallium-68 PSMA PET/CT (concordant, no further disease); the first-visit laboratory tests; and this morning's DXA (femoral neck T-score -2.1, L1 to L4 -1.4)",
        "exam": [
          {
            "system": "General",
            "finding": "Well; walks without help, favoring the right hip slightly; ECOG 1"
          },
          {
            "system": "Musculoskeletal",
            "finding": "Tender over the right iliac crest; no midline spinal tenderness"
          },
          {
            "system": "Neurological",
            "finding": "Strength 5 of 5 in both legs; sensation and reflexes normal"
          },
          {
            "system": "Lymph nodes",
            "finding": "No inguinal or supraclavicular nodes"
          }
        ],
        "assessment": [
          {
            "problem_id": "PRB-002",
            "display": "Prostate adenocarcinoma, Grade Group 4, cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume",
            "assessment": "The diagnosis is confirmed. By the conventional-imaging definition used in the trials and the AUA/SUO guideline, high volume means four or more bone metastases with at least one outside the spine and pelvis, or visceral metastases; he has two bone metastases, both within the spine and pelvis, and no visceral disease, so the disease is low volume. The PSMA PET/CT shows nothing more. He has symptoms from the bone metastasis in the right ilium"
          },
          {
            "problem_id": "PRB-006",
            "display": "Systemic treatment",
            "assessment": "Androgen deprivation should be combined with an androgen receptor pathway inhibitor. Apalutamide, enzalutamide, darolutamide and abiraterone with prednisone are all reasonable. Apalutamide is a single daily tablet without a steroid and improved survival in low-volume disease in the TITAN trial; abiraterone needs prednisone and can worsen blood pressure and glucose, which matters with his hypertension and prediabetes. Docetaxel is not recommended: in low-volume disease it did not clearly improve survival, and triplet therapy is reserved for selected patients with high-volume disease. Apalutamide started a week before the first leuprolide injection also blocks the testosterone flare, so bicalutamide is not needed"
          },
          {
            "display": "Radiotherapy to the prostate",
            "assessment": "In low-volume metastatic disease, radiotherapy to the prostate added to androgen deprivation improved survival in STAMPEDE, and the guidelines support it in selected patients. It is recommended, about six weeks after starting androgen deprivation, as 55 Gy in 20 daily fractions"
          },
          {
            "problem_id": "PRB-009",
            "display": "Bone health and bone metastases",
            "assessment": "Bone-protective drugs at the monthly doses used to prevent skeletal events are recommended in castration-resistant disease; in hormone-sensitive disease, early zoledronic acid did not reduce skeletal events (CALGB 90202). His own fracture risk is the reason to treat: FRAX with androgen deprivation counted gives a hip fracture risk of 3.4 percent, above the 3 percent threshold. Denosumab 60 mg every six months, the osteoporosis dose, is recommended after a dental examination and once vitamin D replacement has begun and calcium is normal. The painful iliac metastasis is likely to settle on androgen deprivation; radiotherapy to that bone remains an option if it does not"
          },
          {
            "display": "Genetic testing",
            "assessment": "Germline testing is recommended for every patient with metastatic prostate cancer, and somatic testing of the tumor for metastatic disease; the results could change later treatment (a PARP inhibitor for a BRCA2 alteration) and would matter for his relatives. Pre-test counseling was done today"
          },
          {
            "problem_id": "PRB-007",
            "display": "Drug interactions and hypertension",
            "assessment": "Apalutamide is a strong CYP3A4 inducer and will lower amlodipine levels, so blood pressure may rise in the first weeks. It also raises the risk of rash, falls, fractures and raised TSH"
          }
        ],
        "recommendations": [
          "Apalutamide 240 mg once daily, starting today",
          "Leuprolide 22.5 mg intramuscularly in one week at this clinic, then every twelve weeks, continuously",
          "No docetaxel for low-volume disease",
          "Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation; radiation oncology planning in about four weeks",
          "Germline testing sent today after counseling; somatic testing on the biopsy tissue",
          "Bone health: cholecalciferol 2000 units daily, calcium 1000 to 1200 mg a day from food, weight-bearing and resistance exercise, a dental examination, then denosumab 60 mg every six months; DXA every one to two years",
          "Acetaminophen for pain; same-day assessment for new leg weakness or numbness or loss of bladder or bowel control",
          "Primary care monitoring: blood pressure at every visit, with the amlodipine dose adjusted as needed; PSA and testosterone at about four weeks and three months, then every three months; blood count and chemistry; TSH before apalutamide and every four months; hemoglobin A1c and lipids at baseline and yearly; rash, falls, hot flashes, fatigue, sexual health, mood and cognition at each visit",
          "Report any rash early: grade 1 or 2 rash is treated with a topical steroid and an antihistamine while apalutamide continues; apalutamide is held for grade 3 rash or any blistering or mucosal involvement"
        ],
        "communication": "Discussed with Dr. Fairweather-Diaz today. The plan was explained in Spanish through a professional interpreter, with a written summary in Spanish. Mr. Neruda chose apalutamide with leuprolide and radiotherapy to the prostate after hearing each option, including docetaxel and abiraterone, and agrees with the plan",
        "follow_up": "Leuprolide injection here in one week. Radiation oncology planning in about four weeks. Medical oncology review at three months with PSA and testosterone, and every three months after that. Primary care sees him at four weeks for blood pressure, the early PSA and the first denosumab dose, and carries out the monitoring above between oncology visits"
      },
      "guideline_ids": [
        "GL-AUA-APC-2026",
        "GL-NCCN-PROSTATE-2026",
        "GL-TITAN-2019",
        "GL-CHAARTED-2018",
        "GL-STAMPEDE-H-2018",
        "GL-CALGB90202-2014",
        "GL-ERLEADA-2026",
        "GL-CMID-2026"
      ]
    }
  },
  "care_plan": {
    "health_concerns": [
      {
        "id": "HC-001",
        "display": "He wants to know what the pain and the urinary symptoms mean, and to be told plainly",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "HC-002",
        "display": "He wants to keep writing every morning and to carry on his duties as ambassador",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "HC-003",
        "display": "He wants important discussions held in Spanish",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      }
    ],
    "goals": [
      {
        "id": "GOAL-001",
        "display": "Diagnosis, staging and a shared treatment decision within three weeks of the first visit",
        "status": "completed",
        "target_date": "2026-06-15",
        "outcome": "Biopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic diagnostic goal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-002",
        "display": "Bone pain controlled, with a pain score of 2 or less and sleep restored",
        "status": "completed",
        "target_date": "2026-07-13",
        "outcome": "Pain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivation",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic symptom goal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-003",
        "display": "PSA of 0.2 ng/mL or less within about seven months of starting treatment",
        "status": "completed",
        "target_date": "2026-09-14",
        "outcome": "PSA 46.8 to 0.18 ng/mL at three months",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic response goal; a PSA of 0.2 ng/mL or less by seven months predicts a better outcome.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-004",
        "display": "Blood pressure below 130/80 mm Hg on androgen deprivation",
        "status": "completed",
        "target_date": "2026-10-05",
        "outcome": "152/90 at four weeks on apalutamide; 128/78 at the annual wellness visit on amlodipine 10 mg",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic cardiovascular goal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-005",
        "display": "Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk",
        "status": "active",
        "target_date": "2026-10-05",
        "outcome": "Denosumab given at four weeks after a dental check; vitamin D 28 ng/mL and rising; walking daily",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone-health goal.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-006",
        "display": "Keep his morning writing and his official duties through treatment",
        "status": "completed",
        "target_date": "2026-10-05",
        "outcome": "Writing every morning; one week of official engagements postponed during radiotherapy",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic goal centered on what matters to him.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      }
    ],
    "interventions": [
      {
        "id": "INT-001",
        "display": "Medical oncology (genitourinary) consultation within two weeks for suspected metastatic prostate cancer: diagnosis, staging, systemic treatment, radiotherapy, bone health and genetic testing",
        "status": "completed",
        "guideline_ids": [
          "GL-NCCN-PROSTATE-2026",
          "GL-AUA-APC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic specialist consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "INT-002",
        "display": "Diagnosis and staging: multiparametric MRI of the prostate, an MRI-targeted transperineal biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan, and PSMA PET/CT",
        "status": "completed",
        "guideline_ids": [
          "GL-NCCN-PROSTATE-2026",
          "GL-AUA-APC-2026",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic staging plan.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "INT-003",
        "display": "Bone pain: acetaminophen 1000 mg up to three times a day; spinal cord compression warning signs explained in Spanish, with same-day assessment for new leg weakness or numbness, or loss of bladder or bowel control",
        "status": "completed",
        "guideline_ids": [
          "GL-NCCN-PROSTATE-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic symptom plan.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "INT-004",
        "display": "Care in Spanish, his first language: a professional medical interpreter for every major discussion, written plans in Spanish, appointments placed around his morning writing and his official duties",
        "status": "completed",
        "guideline_ids": [
          "GL-NCCN-PROSTATE-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic communication plan.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        }
      },
      {
        "id": "INT-005",
        "display": "Systemic therapy: apalutamide 240 mg daily from the consultation day and leuprolide 22.5 mg every twelve weeks from one week later, continuous; docetaxel not added for low-volume disease",
        "status": "completed",
        "guideline_ids": [
          "GL-AUA-APC-2026",
          "GL-NCCN-PROSTATE-2026",
          "GL-TITAN-2019",
          "GL-CHAARTED-2018"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic systemic treatment decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "recorded_date": "2026-06-15"
      },
      {
        "id": "INT-006",
        "display": "Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation, for low-volume metastatic disease",
        "status": "completed",
        "guideline_ids": [
          "GL-AUA-APC-2026",
          "GL-NCCN-PROSTATE-2026",
          "GL-STAMPEDE-H-2018"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic local treatment decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "recorded_date": "2026-06-15"
      },
      {
        "id": "INT-007",
        "display": "Germline genetic testing with pre-test counseling, and somatic testing of the biopsy tissue",
        "status": "completed",
        "guideline_ids": [
          "GL-AUA-APC-2026",
          "GL-NCCN-PROSTATE-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic testing plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "recorded_date": "2026-06-15"
      },
      {
        "id": "INT-008",
        "display": "Bone health on androgen deprivation: DXA and FRAX, cholecalciferol 2000 units a day, calcium 1000 to 1200 mg a day from food, weight-bearing exercise, a dental examination, then denosumab 60 mg every six months for high fracture risk; DXA again in one to two years",
        "status": "completed",
        "guideline_ids": [
          "GL-AUA-APC-2026",
          "GL-CMID-2026",
          "GL-CALGB90202-2014"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone-health plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "recorded_date": "2026-06-15"
      },
      {
        "id": "INT-009",
        "display": "Monitoring on androgen deprivation and apalutamide: PSA and testosterone every three months, blood count and chemistry, TSH every four months, blood pressure at every visit, hemoglobin A1c and lipids, rash, falls, hot flashes, sexual health, fatigue, mood and cognition",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-ERLEADA-2026",
          "GL-AUA-APC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic monitoring plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:00:00-05:00"
        },
        "recorded_date": "2026-06-15"
      },
      {
        "id": "INT-010",
        "display": "Apalutamide rash: triamcinolone 0.1% cream twice daily for two weeks, cetirizine 10 mg daily, fragrance-free emollient, continue apalutamide; stop it and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skin",
        "status": "completed",
        "guideline_ids": [
          "GL-ERLEADA-2026",
          "GL-NCCN-PROSTATE-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic plan decided at the sick visit.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        },
        "recorded_date": "2026-08-10"
      },
      {
        "id": "INT-011",
        "display": "Atorvastatin 20 mg daily for primary prevention, with a lipid panel and ALT in six to twelve weeks",
        "status": "completed",
        "guideline_ids": [
          "GL-USPSTF-STATIN-2022",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic statin decision at the annual wellness visit.",
          "author": "The Human Record generator",
          "created": "2026-11-06T15:30:00-05:00"
        },
        "recorded_date": "2026-10-05"
      }
    ],
    "guidelines": [
      {
        "guideline_id": "GL-NCCN-PROSTATE-2026",
        "title": "NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer",
        "publisher": "National Comprehensive Cancer Network",
        "url": "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-AUA-APC-2026",
        "title": "Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026",
        "publisher": "American Urological Association and Society of Urologic Oncology",
        "url": "https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-AUA-APC-2023",
        "title": "Lowrance W, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol 2023;209(6):1082-1090",
        "publisher": "American Urological Association and Society of Urologic Oncology",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37096583/",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-TITAN-2019",
        "title": "Chi KN, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer (TITAN). N Engl J Med 2019;381(1):13-24",
        "publisher": "New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31150574/",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-CHAARTED-2018",
        "title": "Kyriakopoulos CE, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 2018;36(11):1080-1087",
        "publisher": "Journal of Clinical Oncology",
        "url": "https://pubmed.ncbi.nlm.nih.gov/29384722/",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-STAMPEDE-H-2018",
        "title": "Parker CC, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392(10162):2353-2366",
        "publisher": "The Lancet",
        "url": "https://pubmed.ncbi.nlm.nih.gov/30355464/",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-CALGB90202-2014",
        "title": "Smith MR, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol 2014;32(11):1143-1150",
        "publisher": "Journal of Clinical Oncology",
        "url": "https://pubmed.ncbi.nlm.nih.gov/24590644/",
        "version_or_year": "2014"
      },
      {
        "guideline_id": "GL-ERLEADA-2026",
        "title": "ERLEADA (apalutamide) tablets: prescribing information",
        "publisher": "Janssen Products, LP, via DailyMed (National Library of Medicine)",
        "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-ACS-PCA-SURV-2014",
        "title": "Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249",
        "publisher": "American Cancer Society",
        "url": "https://pubmed.ncbi.nlm.nih.gov/24916760/",
        "version_or_year": "2014"
      },
      {
        "guideline_id": "GL-CMID-2026",
        "title": "CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/topthirty/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-AWV-CMS",
        "title": "Medicare Wellness Visits (Medicare Learning Network)",
        "publisher": "Centers for Medicare & Medicaid Services",
        "url": "https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-PREV-2026",
        "title": "Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/preventative_services/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-CRC-2021",
        "title": "Colorectal Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-USPSTF-STATIN-2022",
        "title": "Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication",
        "version_or_year": "2022"
      },
      {
        "guideline_id": "GL-USPSTF-AAA-2019",
        "title": "Abdominal Aortic Aneurysm: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/abdominal-aortic-aneurysm-screening",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-USPSTF-FALLS-2024",
        "title": "Falls Prevention in Community-Dwelling Older Adults: Interventions",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/falls-prevention-community-dwelling-older-adults-interventions",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-USPSTF-HCV-2020",
        "title": "Hepatitis C Virus Infection in Adolescents and Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening",
        "version_or_year": "2020"
      },
      {
        "guideline_id": "GL-CDC-IMZ-2026",
        "title": "Adult Immunization Schedule by Age",
        "publisher": "Centers for Disease Control and Prevention",
        "url": "https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html",
        "version_or_year": "2026"
      }
    ]
  },
  "review": {
    "schema_validation": {
      "status": "not_started",
      "notes": "Run scripts/build.ps1 -Conformance."
    },
    "clinical_review": {
      "status": "not_started",
      "notes": "Awaiting clinician review; check the low-volume classification on conventional imaging with a concordant PSMA PET/CT, apalutamide rather than abiraterone or enzalutamide, no docetaxel, radiotherapy to the prostate, apalutamide started one week before leuprolide for flare protection, denosumab at the osteoporosis dose rather than a bone agent for skeletal events, the amlodipine interaction, the grade 2 rash managed without stopping apalutamide, and the missed baseline TSH."
    },
    "provenance_review": {
      "status": "not_started",
      "notes": "Sources: the Nobel Prize biography, the Library of the National Congress of Chile, the National Library of Chile (Memoria Chilena), and AP, AFP, CBS, Smithsonian, Globe and Mail and NPR reporting on the forensic investigations. The Fundación Pablo Neruda pages, the New York Times and The Guardian were not read. The posting to France is dated January 1971, not 1970."
    },
    "safe_messaging_review": {
      "status": "not_started",
      "notes": "The dispute over his death is recorded as R disputed, taking no side. No relative or other real person is named in the modern episode or given a statement, decision or health fact; relatives quoted in the news reports are not used. Mood screening is synthetic and below the thresholds for a safety assessment."
    }
  }
}
